

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of a short term multifactorial treatment program on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019214
Article Type:	Research
Date Submitted by the Author:	17-Aug-2017
Complete List of Authors:	Safai, Narges; Steno Diabetes Center Copenhagen, Patient Care Carstensen, Bendix; Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology Vestergaard, Henrik; The Novo Nordisk Foundation, Center for Basic Metabolic Research, Section of Metabolic Genetics Ridderstråle, Martin; Novo Nordisk AS; Lunds Universitet, Department of Clinical Sciences
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Diabetes and endocrinology, Medical management
Keywords:	Type 2 diabetes, Glycemic control, Outcomes, CVD risk, Multifactorial treatment

SCHOLARONE™
Manuscripts

Only

1
2
3
4 **Title page**
5

6
7 **Impact of a short term multifactorial treatment program on clinical outcomes and**
8
9 **cardiovascular risk estimates: a retrospective cohort study**
10

11
12
13
14 5 Narges Safai^a, Bendix Carstensen^b, Henrik Vestergaard^c and Martin Ridderstråle^d

15
16 ^a Steno Diabetes Center Copenhagen, Gentofte, Denmark; narges.safai@regionh.dk

17
18 ^b Steno Diabetes Center Copenhagen, Gentofte, Denmark; bendix.carstensen@regionh.dk

19
20 ^c Novo Nordisk Foundation of Basic Metabolic Research, University of Copenhagen,
21
22 Denmark; Henrik.vestergaard@sund.ku.dk

23
24 ^d Novo Nordisk A/S, Søborg, Denmark and Department of Clinical Sciences, Lund
25
26 University, Malmö, Sweden; mtrd@novonordisk.com
27

28
29
30
31 Corresponding author:

32
33 14 Narges Safai, MD

34
35 15 Steno Diabetes Center Copenhagen

36
37 16 Niels Steensens Vej 2-4

38
39 17 DK-2820 Gentofte

40
41 18 Denmark

42
43 19 +45 3091 3395 (direct)

44
45 20 narges.safai@regionh.dk

46
47
48 21 Number of tables: 2

49
50 22 Number of figures: 3

51
52
53 23

1
2
3 **Abstract**

4 **Objectives:** To investigate the impact of a short term multifactorial treatment program in a
5
6 real-life setting on clinical outcomes and estimated cardiovascular disease (CVD) risk.

7
8 **Design:** A retrospective observational cohort study, using data from the electronic medical
9
10 records and national registers.

11
12 **Setting:** Tertiary diabetes center in Denmark.

13
14 **Participants:** Patients with type 2 diabetes ($n=4,299$) referred to a short term treatment
15
16 program between Jan 1st 2001 and April 1st 2016.

17
18 **Outcomes:** Primary outcomes were HbA1c, blood pressure and LDL cholesterol and changes
19
20 in pharmacological treatment. Our secondary outcome was the impact on estimated CVD
21
22 risk.

23
24 **Results:** The patients achieved a mean \pm SD decrease in HbA1c, systolic and diastolic blood
25
26 pressure (BP), and LDL cholesterol of $1.16\pm 0.04\%$ (12.7 ± 0.4 mmol/mol), 6.3 ± 0.4 mmHg,
27
28 2.6 ± 0.2 mmHg and 0.40 ± 0.02 mmol/l, respectively ($p<0.0001$). The proportion of patients
29
30 who met the treatment goal for HbA1c ($<7\%$ [<53 mmol/mol]) increased from 31% to 58% (p
31
32 <0.0001); for BP ($<130/80$ mm Hg) from 24% to 34% ($p <0.0001$), and for LDL cholesterol
33
34 (<2.5 mmol/l (patients without previous CVD) or <1.8 mmol/l (patients with previous CVD))
35
36 from 52% to 65%. Those reaching all three guideline treatment targets increased from 4% to
37
38 15% ($p<0.0001$), and when relaxing the BP target to $<140/85$ from 8% to 24%. The estimated
39
40 CVD risk was relatively reduced by 15.2% using the Swedish NDR Risk Engine and 30.9%
41
42 using the UKPDS risk engine.

43
44 **Conclusions:** Our data support that short term multifactorial treatment of patients with
45
46 glycemic dysregulation in a specialist outpatient setting is both achievable and effective, and
47
48 associated with a clinically meaningful improvement in CVD risk.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Strengths and limitations of this study**
4

- 5 2 • Large cohort of dysregulated patients with type 2 diabetes under real-world conditions
6
7 3 and strong validity of data with repeated recordings of clinical measurements and
8
9 4 access to national registries.
10
11 5 • Selection bias in terms of more motivated and high risk patients being referred to the
12
13 6 clinic, and by exclusion of those who did not show up.
14
15
16 7 • The use risk engines can only give an estimate of the CVD risk and the UKPDS risk
17
18 8 engine is based on a population many years prior to ours where treatment guidelines
19
20 9 were different.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11 **Keywords:** Type 2 diabetes, glycaemic control, outcomes, CVD risk and multifactorial
12 treatment
13
14
15
16

1 **Introduction**

2 Type 2 diabetes is an increasing global health threat. It is estimated that 439 million people
3 will be diagnosed with diabetes by 2030 (1). Type 2 diabetes is associated with an increased
4 risk of microvascular complications such as nephropathy, neuropathy, and retinopathy as well
5 as macrovascular disease, resulting in a decreased life expectancy and substantial personal
6 and societal expenses (2). Ensuring good glycaemic control remains the most effective
7 therapeutic measure to reduce the risk of developing microvascular disease (3, 4).

8 Multifactorial treatment with tight control of glycaemia, blood pressure (BP) and lipids,
9 accompanied by acetylsalicylic acid and lifestyle advice, is known to reduce progression of
10 microvascular complications, cardiovascular disease (CVD), and mortality by 50% in patients
11 with type 2 diabetes and microalbuminuria (5-7). Consequently, diabetes guidelines have
12 advocated an intensified treatment approach aiming at addressing and reducing all CVD risk
13 factors in patients with diabetes since several years (8, 9).

14
15 For most patients, sufficient glycaemic, BP and lipid control can be achieved in a primary care
16 setting but in high risk patients, or in patients with complex treatment regimens, the
17 proportion of patients who achieves metabolic control in primary care decreases (10, 11). In
18 this situation, in most health care systems, high risk patients are referred to specialist clinics
19 for evaluation. A broad risk factor intervention in this subgroup has proven particularly
20 effective in the Steno-2 study (5). However, it remains unknown whether the results seen in
21 the study setting can be achieved in clinical practice.

22
23 The overall aim of this study was to describe how the multifactorial intervention methods
24 from the Steno-2 study perform in a larger scale clinical setting. Our primary objective was to
25 describe changes in metabolic outcomes and pharmacological treatment as a result of such

1 structured short term intervention. Our secondary objective was to evaluate the impact on
2 estimated CVD risk by using two different risk assessment tools: the UKPDS Risk Engine
3 (12), and the 5-year Swedish National Diabetes Registry (NDR) risk model (13).
4

5 **Methods**

6 **Study Population**

7 This study is based on patients referred to Steno Diabetes Center, a tertiary multidisciplinary
8 and highly specialized diabetes center in the Capital Region of Denmark. It serves as one out
9 of three referral centers with a catchment area of over 1.7 million people and provides
10 diabetes care on a permanent basis to about 5.600 patients. During the Steno-2 study, SDC
11 designed a treatment program algorithm specifically for patients with type 2 diabetes and
12 glycemic dysregulation. The primary goal of the program is to improve patient quality of life
13 and reduce mortality by prevention of acute and chronic complications of diabetes. This is
14 done by motivating and encouraging self-management, professional support in behavioral
15 changes, and pharmacological treatment according to national and international guidelines.
16 The SDC Type 2 Clinic (T2C) opened in 2001, providing care for patients referred from
17 general practitioners (GPs) or other hospitals in the region. Patients were referred to the clinic
18 either as newly diagnosed with a need for education and start of treatment, requiring a shift to
19 insulin treatment, having micro- or macrovascular complications, or having glycemic
20 dysregulation in spite of attempts to control the disease by the GP. The program, which is still
21 running, involves a consultation with a nurse, a dietician, and a physician in a structured
22 order with specific assignments and is comparable to the intensive treatment arm of the
23 Steno-2 study (Figure 1). The individual visits are complemented by optional group-based
24 theme sessions with the overall aim of facilitating patient empowerment. The treatment
25 program consist of self-management training with a focus on knowledge, lifestyle behavior

1 including diet, physical activity and smoking cessation, skills to improve glycemic control
2 such as self-monitoring of blood glucose and skills to prevent and identify complications.
3 Furthermore, there is focus on pharmacological treatment of hyperglycemia, hypertension
4 and dyslipidemia. After approximately eight months, patients were evaluated for referral back
5 to their GP, or to continue at the SDC outpatient clinic. The structure of program has
6 remained unchanged in the study period while e.g. medications used have followed updated
7 treatment guidelines. We defined the baseline and evaluation follow-up visits as the first and
8 last visit to the T2C, respectively. This study is a retrospective observational study with
9 demographics, clinical, and laboratory information extracted from the electronic medical
10 records and laboratory database of SDC. We included all patients who had finalized a
11 treatment program between 1st of January 2001 and 1st of April 2016 ($n = 4,489$), and to
12 avoid no-shows, once off or very brief consultations we excluded patients with a treatment
13 duration under 30 days (i.e. between the baseline and follow-up visits, $n = 190$). We ended up
14 with a total of $n = 4,299$ patients. 16% of the patients were subsequently re-referred to the
15 clinic, but we only included their first treatment program here.

16 17 Anthropometric, clinical and biochemical measurements

18 Laboratory analyses at the baseline visit were encouraged to be fasting and included: glucose,
19 HbA_{1c}, hemoglobin, creatinine, total-cholesterol, high-density lipoprotein-cholesterol (HDL)
20 cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides (TG), C-peptide and
21 urine albumin. At all in-between visits and at follow-up an HbA_{1c}, BP and weight were
22 measured. All laboratory and anthropometric measurements were recorded using
23 standardized procedures at the SDC accredited laboratory (ISO 15189). Body mass index
24 (BMI) was calculated from weight and height (kg/m^2). A person was considered overweight
25 at $\text{BMI} \geq 25 \text{ kg/m}^2$, and obese at $\text{BMI} \geq 30 \text{ kg/m}^2$. For BP and heart rate automated

1
2
3 1 oscillometric blood pressure recorders were used (AND UA-787plus, A&D medical,
4 California, USA). Smoking status was obtained at every visit.

5
6
7 3
8
9 4 Diabetes complications and treatment

10 5 Micro albuminuria was here defined as a morning urine sample with urine albumin of 30-300
11 mg/L or urine albumin to creatinine ratio > 30 mg/g to 300 mg/g at the first visit. Macro

12 6 albuminuria likewise but with a value > 300 mg/L or > 300 mg/g. Peripheral neuropathy was
13 7 defined by examining vibration sensation with a biothesiometer and using an age-adjusted

14 8 threshold (14). Information on cardiovascular disease was obtained from The National Patient
15 9 Register and included diagnosis from 1977 till 2015 and procedures from 1995 till 2015.

16 10 Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery,
17 11 ischaemic heart disease, heart insufficiency, atrial fibrillation, vascular surgery, stroke,
18 12 transitory cerebral ischaemia and amputations using ICD-8 and ICD-10 codes.

19 13 Information on medication was obtained by Register of Medicinal Products Statistics, where
20 14 individual-level data on all prescription drugs sold in Danish community pharmacies since
21 15 1994 has been recorded and administered by Statistics Denmark (15). A person was defined
22 16 as being on a treatment at baseline if they had purchased a prescribed drug less than 180 days
23 17 before their first visit and at follow-up if they purchased a prescribed drug after their first
24 18 visit and less than 30 days after their last visit.

25 19 Permission to use data from the patient register was obtained from the Danish Data Protection
26 20 Agency (ref. number: 2007-58-0015) and from the Danish Patient Safety Authority.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 22
44 23 Statistical methods

45 24 We investigated how many patients reached the recommended targets for HbA1c (A), BP (B)
46 25 and LDL cholesterol (C) according to national guidelines (16), collectively referred to as

1
2
3 1 ABC control: HbA_{1c} < 7% (< 53 mmol/mol), BP < 130/80 mm Hg and LDL cholesterol <
4
5 2 2.5 mmol/l (< 100 mg/dl, patients without previous CVD) or < 1.8 mmol/l (< 70 mg/dl,
6
7 3 patients with previous CVD). The primary outcomes were changes in blood glucose control
8
9 4 (HbA_{1c}), BP and lipids from first visit (baseline) to end of treatment (follow-up evaluation
10
11 5 visit). Secondary outcomes were the proportion of patients achieving the recommended
12
13 6 targets for A, B or C and all three, ABC. For blood lipids, the T2C program assumed they
14
15 7 would not deteriorate if they were on target at baseline and measurements were only repeated
16
17 8 in case they were not at target at baseline. Accordingly, for this analysis a last observation
18
19 9 carried forward approach was used to impute missing data. To evaluate the effect of changes
20
21 10 in metabolic outcomes on the estimated risk of CVD, we calculated CVD risk at baseline and
22
23 11 at follow-up using two different risk assessment tools: a Swedish risk model specific for type
24
25 12 2 diabetes (13) and the UKPDS Risk Engine (12). The Swedish model is based on patients
26
27 13 with type 2 diabetes using 12 predictors derived from a large observational sample of patients
28
29 14 ($n = 24,288$) in the Swedish National Diabetes Register (NDR) followed from 2002 to 2007
30
31 15 and estimates the 5-year risk of CVD. The UKPDS Risk Engine is also type 2 diabetes-
32
33 16 specific and based on 4,540 patients from the UKPDS trial (1977 to 1991). It includes HbA_{1c}
34
35 17 as a continuous variable and calculates the risk of developing a new coronary heart disease
36
37 18 (CHD) event. *T* test was used for gender differences. Comparison between baseline and
38
39 19 follow-up was made using mixed model for repeated measurements (MMRM) for continuous
40
41 20 variables and logistic regression for dichotomous variables. McNemar test was used to
42
43 21 compare changes in categorical variables. For risk estimates, exact 95%-confidence intervals
44
45 22 (CI) were calculated. SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC) was used for
46
47 23 database management and all of the above-mentioned analyses.
48
49
50
51
52
53
54
55
56
57
58
59
60

25 **Results**

1 Study cohort characteristics

2 Baseline characteristics of the study cohort are shown in Table 1. The majority of patients
3 were Caucasians, and 19% were diagnosed with diabetes within a year before their referral.
4 There were more males ($n = 2,567$) than females ($n = 1,732$) but no difference in treatment
5 duration: median treatment program duration was 8.4 months (IQR: 6.1, 11.3). There were
6 more male smokers and ex-smokers. Males had a higher level of HbA_{1c}, BP, weight and TG
7 but lower BMI and cholesterol levels at baseline (Table 1).

9 Metabolic outcomes

10 There was a significant decrease in HbA_{1c} between baseline and follow-up of $1.0 \pm 0.04\%$
11 (10.6 ± 0.4 mmol/mol), with no gender difference. The decrease in systolic BP was 6.3 ± 0.4
12 mm Hg and in diastolic BP 2.7 ± 0.2 mm Hg ($p < 0.0001$ for both). The effect of treatment on
13 BP was the same in both genders. There was a significant decrease in total-cholesterol, LDL
14 and TG of 0.39 ± 0.03 mmol/l, 0.32 ± 0.02 mmol/l and 0.22 ± 0.05 mmol/l, respectively.
15 There was no change in HDL levels overall ($p = 0.2$). As expected, females had higher HDL
16 levels than males, both at baseline and at follow-up ($p < 0.0001$). This gender difference was
17 also seen for total- and LDL cholesterol levels where females had higher levels at both
18 baseline and follow-up. The effect of treatment on lipid levels was equal in both genders.

20 ABC control

21 In general, the proportion of patients achieving full ABC control according to national
22 guideline treatment targets (HbA_{1c} $< 7\%$ [< 53 mmol/mol]), LDL < 2.5 mmol/l (< 100 mg/dl,
23 patients without previous CVD) or < 1.8 mmol/l (< 70 mg/dl, patients with previous CVD),
24 and BP $< 130/80$ mm Hg) increased from 4% to 15% ($p < 0.0001$). More females were
25 achieving all three treatment targets at both baseline ($p = 0.047$) and at follow-up ($p = 0.014$).

1 Patients achieving the HbA_{1c} target increased from 31% to 58% ($p < 0.0001$), the BP target
2 from 24% to 34% ($p < 0.0001$), and the LDL target from 52% to 65% ($p = 0.002$, Figure 2).
3 If the BP target was relaxed from $< 130/80$ mm Hg to $< 140/85$ mm Hg the percentage
4 achieving the BP target increased from 43% at baseline to 58% at follow-up ($p < 0.0001$),
5 and consequently full ABC control from 8% at baseline to 24% at follow-up ($p < 0.0001$).

6 7 Changes in pharmacological treatment

8 The most common antidiabetic drug at baseline was metformin, which 58.4% of the patients
9 were on, followed by sulphonyl urea (SU), 38.4%, and insulin, 19.5% (Figure 3). Only a
10 small proportion of patients were on dipeptidyl peptidase 4 (DPP-4) inhibitors, 7.0%,
11 glucagon-like peptide 1 (GLP-1) analogues, 3.9%, or other antidiabetic drug, 4.2%. In
12 general there was an increase in the use of medication during the program. The largest
13 increase was seen in use of metformin to 75.3%, insulin to 36.9% and GLP1-analogues to
14 11.6%. While SU only increased slightly to 41.8%, DPP-4 inhibitors to 9.6% and other
15 antidiabetics 4.3%.

16 As part of the multifactorial treatment program, we also observed an increase in use of
17 antihypertensive drugs to 75.3%, lipid lowering drugs to 75.9% and acetylsalicylic acid
18 (ASA) to 69.6%.

19 20 Changes in cardiovascular risk

21 Estimated baseline and follow-up cardiovascular risk according to the used risk engines are
22 shown in Table 2. Using the Swedish NDR model which predicts the 5 year risk of a new
23 CVD event in a diabetic population, we observed a relative risk reduction of 15.2% (95% CI:
24 14.5-15.9). The UKPDS risk engine showed a relative risk reduction of 30.9% (95% CI:
25 30.3-31.5) in the 5 year CHD risk estimate. Females had a lower risk than males both at

1
2
3 1 baseline and at follow-up according to both risk models ($p < 0.0001$). Meanwhile, both
4
5 2 according to the Swedish NDR model and the UKPDS risk engine, females had a smaller
6
7 3 relative risk reduction compared to males ($p < 0.0001$).
8
9 4

11 5 **Discussion**

13 6 This study shows that a short term targeted multifactorial treatment program in a specialized
14
15 7 clinical setting can improve metabolic outcome measures and CVD risk in patients with type
16
17 8 2 diabetes and high prevalence of complications. This confirms that multifactorial treatment
18
19 9 not only works in a clinical study setting, but is also feasible and effective in real world
20
21 10 clinical practice. With a specialized group of health care providers and a structured treatment
22
23 11 and educational program that focuses on lifestyle intervention, self-management training and
24
25 12 pharmacological treatment of hyperglycemia, hypertension and dyslipidemia, it is possible to
26
27 13 accomplish significant CVD risk reductions in a high risk population with diabetes.
28
29 14

33 15 **Treatment targets**

35 16 Intensive multifactorial intervention in high risk patients has previously been shown to reduce
36
37 17 CVD and mortality (7), and a recent 21 years follow-up of the Steno-2 study population
38
39 18 shows that patients in the intensive-therapy group survived for a median of 7.9 years longer
40
41 19 than the conventional-therapy group patients (17). Here we show that the same treatment
42
43 20 program also works in clinical practice in a more diverse population, and results in a
44
45 21 substantial reduction of 5- and 10-year CVD risk as estimated by two of the available and
46
47 22 commonly used risk engines. In terms of risk factor intervention, glucose control continuous
48
49 23 to be the greatest challenge to diabetes care. Nonetheless, all but 21% of patients changed
50
51 24 from a higher to a lower HbA_{1c} category in this follow-up. For example, 84% of patients with
52
53 25 an HbA_{1c} < 6.5% (< 48 mmol/mol) remained < 6.5% (< 48 mmol/mol) and 75% of patients
54
55
56
57
58
59
60

1 with an HbA_{1c} > 9% (> 75 mmol/mol) improved their HbA_{1c} to ≤ 9% (≤ 75 mmol/mol).
2 Importantly, the improvement in glycaemic control was not accompanied by a general
3 increase in weight. In fact, although we found that 15% of those in the normal weight
4 category shifted to the overweight category when comparing the changes in BMI categories,
5 15% of those who were in the obese or overweight category dropped to a lower weight
6 category. The weight gain observed in some patients is probably explained by the increased
7 use of insulin, while weight loss in others can be explained by an increased use of GLP-1
8 receptor agonist treatment in recent years along with lifestyle management including dietary
9 and physical activity advice.

10
11 With focus on hyperglycemia, hypertension and dyslipidemia, we found an increase in the
12 proportion of patients achieving the recommended targets that are comparable to intervention
13 studies (18, 19). Here, the relative proportion of patients achieving HbA_{1c} < 53 mmol/mol
14 (7%) nearly doubled, BP < 130/80 mm Hg increased by 42% and LDL < 2.5 mmol/l by 25%.
15 The T2C treatment program in this complex high-risk cohort resulted in a higher prevalence
16 of risk factors in control equal to what has been observed in the more general diabetes
17 population in the National Health and Nutrition Examination Surveys (NHANES) from 2007
18 to 2010 (20). The NHANES data differ in the way that their data was cross-sectional with
19 participants with self-reported diabetes, without any distinction between type 1 and type 2,
20 and with a different risk profile. Our population was more selected by being referred from
21 their GP and requiring specialized care, which means they either had more comorbidities or a
22 more complex treatment than the general patient with type 2 diabetes. For HbA_{1c} 58% in our
23 cohort achieved the treatment target vs 53% in the NHANES cohort and for LDL-cholesterol
24 65% vs 56%, respectively. But for BP there was a big difference, 34% in our cohort vs. 51%
25 in the NHANES cohort. This could be due to a higher prevalence of high BP in a group of

1 patients selected for complex disease with long duration. We did observe a time trend in the
2 data as the proportion of patients achieving the stringent BP target increased from 23% in
3 2001 to 44% in 2015. The same improvement trend over time was observed in the proportion
4 of patients achieving all three ABC targets; 7% in 2001 increasing to an average of 16% from
5 2006 and forward in our material and in the NHANES data from 7% in 1999-2002 to 19% in
6 2007-2010.

7 8 Use of CVD risk engines

9 To estimate the CVD risk in patients with type 2 diabetes is helpful to follow-up on treatment
10 and to target further measures to patients at risk. In this study we used two different CVD risk
11 engines to estimate the effect of the treatment program. The UKPDS risk engine is diabetes-
12 specific and has several advantages as it incorporates HbA_{1c} and diabetes duration as
13 continuous variables (12). However, it is still not ideal as it is based on the patients recruited
14 by UKPDS for randomization in a clinical trial two decades ago before newer and more
15 effective treatments were available or widely used (e.g. statins, angiotensin converting
16 enzyme inhibitors and antidiabetic drugs). Accordingly, recent validation showed poor
17 calibration and overestimation of the CHD risk (21). A model that seems more suitable for
18 our population is the Swedish NDR risk model, which is based on a more recent and
19 nationwide population, reflecting a more diverse population and taking into account the
20 history of previous CVD and BMI. By using this model we found a relative reduction in the
21 estimated 5-year CVD risk of 16%, after approximately eight months, despite the increase in
22 age and diabetes duration. Notably, the fact that 26% of the patients had a prior CVD
23 diagnosis at baseline reflects the high risk profile and complexity of the population that was
24 referred to the treatment program. This of course does not normalise their actual risk, which
25 will still be high, but can be a motivating factor for the patients that there are some

1
2
3 1 modifiable risk factors that can reduce their risk. In comparison, the population used in the
4
5 2 Swedish model had a mean risk of 11.9% and a 5-year risk of fatal/non-fatal CVD of more
6
7 3 than 10% is defined as high risk. According to this 92% of our population was in high risk at
8
9 4 baseline. The UKPDS risk engine which estimates the risk of the first CHD event in 5 or 10
10
11 5 years, gives a lower 5 and 10 year risk estimate at baseline than the Swedish model, 7.4% and
12
13 6 17.1% respectively. This is nearly the same as the 10-year risk found in a NHANES
14
15 7 population from 2007 to 2012 of 16.5% if no risk factors were in control and 10.2% if all risk
16
17 8 factors were in control when using the same risk engine (22).

19
20 9 Interestingly, both the NDR and UKPDS risk engines estimated a higher CVD risk reduction
21
22 10 in males than in females. This, perhaps expected finding, can be due to a relatively greater
23
24 11 HbA_{1c} reduction seen in males, which is used in both the NDR and the UKPDS risk engines.
25
26 12 However, this alone could not explain the whole difference, as the gender difference
27
28 13 remained significant after excluding HbA_{1c} from the equation. This in spite a higher
29
30 14 percentage of females achieved the metabolic targets.
31
32

33 15

34 16 Strengths and limitations

35
36
37 17 Strengths of this study include the validity of data with repeated recordings of the HbA_{1c} and
38
39 18 BP at each visit, and that it includes a large cohort of patients treated under real-life
40
41 19 conditions such that results might have greater external validity than the highly selected
42
43 20 populations in randomized controlled trials (RCT). Still, we cannot rule out that there might
44
45 21 be a selection bias in terms of more motivated patients being referred to the clinic, and by
46
47 22 exclusion of those who did not show up.

48
49
50 23 As a result of using a database and a register, we do not have complete data on all patients
51
52 24 and therefore the cohort size changes a bit as results are based on those without missing
53
54 25 values. Another limitation is that there is a lack of patient reported outcomes, such as adverse
55
56
57
58
59
60

1
2
3 1 events of drugs and general well-being. This was not possible to extract from the electronic
4
5 2 medical records. Furthermore we cannot be sure that the patients going through a treatment
6
7 3 program actually completed the program or was discharged for other reasons. It is also
8
9 4 important to acknowledge that most of the treatment programs analyzed here were completed
10
11 5 before many of the new anti-diabetic treatments, as GLP1-analogs and sodium-glucose co-
12
13 6 transporter 2 (SGLT2)-inhibitors, were widely used and before acceptance of a more
14
15 7 personalized treatment as recommended in the position statement from ADA and EASD in
16
17 8 2012 (23). Another limitation of this study is the use risk engines that only give an estimate
18
19 9 of the CVD risk and that UKPDS is based on a population many years prior to ours and
20
21 10 treatment guidelines were not the same.
22
23
24 11 Meanwhile, the data serves as a baseline benchmark for real world data studies as to what can
25
26 12 be achieved in routine clinical practice before these treatments and guidelines get wider use
27
28 13 and implementation. The use of a more individualized treatment approach with involvement
29
30 14 of the patient in decision making is increasingly used in the treatment programs at the
31
32 15 moment and is expected to increase adherence to therapy. Furthermore, the combination of a
33
34 16 more individualized HbA_{1c} target and a broader selection of antidiabetic, antihypertensive
35
36 17 and dyslipidemia treatment will likely increase the proportion of patients achieving their
37
38 18 treatment goals and thereby reduce their CVD risk and mortality. Specifically, since the
39
40 19 EMPA-REG OUTCOME trial showed a 38% and the LEADER trial a 22% relative risk
41
42 20 reduction in deaths from CVD events (24, 25) in patients with type 2 diabetes and a high risk
43
44 21 of cardiovascular events, this gives us further treatment options in this patient group.
45
46 22 Therefore constant evaluation of the effects of our treatments on the risk of CVD or mortality
47
48 23 is necessary. Combining these drugs, the treatment program evaluated here, and an
49
50 24 individualized approach would be a logical next step for future studies.
51
52
53
54
55
56
57
58
59
60

1
2
3 1 Conclusion

4
5 2 This study of patients with type 2 diabetes who undergo structured treatment program lasting
6
7 3 less than one year show that it is possible to increase the proportion of patients achieving the
8
9 4 target levels for HbA_{1c}, BP, and LDL, thereby reducing their estimated CVD and CHD risk.
10
11 5 To the strengths of such a structured program we count the focus on treatment targets by a
12
13 6 multidisciplinary team and the fact that it is time limited, which reduces clinical inertia and
14
15 7 costs. Our results show that intensive treatment is not only effective in the RCT setting, but
16
17 8 also in clinical practice and should encourage other health care systems to establish similar
18
19 9 programs.
20
21

22 10

23
24 11
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 14
5 2 **Conflicts of interest**

6
7 3 NS, BC and HV were employed at Steno Diabetes Center A/S, now known as Steno Diabetes
8
9 4 Center Copenhagen and MR was employed there when the study was initiated. Steno
10
11 5 Diabetes Center A/S was a research hospital working in the Danish National Health Service
12
13 6 and owned by Novo Nordisk A/S. NS and BC own shares in Novo Nordisk A/S.

14
15
16 7 **Funding**

17
18 8 This study has been funded by Innovation Fund Denmark

19
20 9 **Contribution statement**

21
22 10 NS and BC were responsible for data management and statistical analysis. NS and MR were
23
24 11 responsible for interpretation of data and writing of the article. HV was responsible
25
26 12 interpretation and critical revision of the article. All authors fully approved the final version
27
28 13 of the article.

29
30
31 14 **Data sharing statement**

32
33 15 Clinical data will be available at request, but information on diagnosis and medication is not
34
35 16 allowed to be shared by the Danish National Patient Register or Statistics Denmark.

36
37
38
39 17
40 18 **Uncategorized References**

- 41
42 19 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE.
43 20 Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes*
44 21 *research and clinical practice*. 2014;103(2):137-49.
45 22 2. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et
46 23 al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a
47 24 collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-
48 25 22.
49 26 3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of
50 27 intensive glucose control in type 2 diabetes. *The New England journal of medicine*.
51 28 2008;359(15):1577-89.
52 29 4. UKPDS. Effect of intensive blood-glucose control with metformin on
53 30 complications in overweight patients with type 2 diabetes (UKPDS 34). *UK Prospective*
54 31 *Diabetes Study (UKPDS) Group. Lancet*. 1998;352(9131):854-65.
55 32 5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
56 33 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
57 34 *The New England journal of medicine*. 2003;348(5):383-93.

- 1 6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin
2 compared with conventional treatment and risk of complications in patients with type 2
3 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*.
4 1998;352(9131):837-53.
- 5 7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a
6 multifactorial intervention on mortality in type 2 diabetes. *The New England journal of*
7 *medicine*. 2008;358(6):580-91.
- 8 8. IDF Clinical Guidelines Task Force. Global guideline for Type 2
9 diabetes. . Brussels: International Diabetes Federation; 2005.
- 10 9. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F,
11 et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed
12 in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and
13 cardiovascular diseases of the European Society of Cardiology (ESC) and developed in
14 collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart*
15 *J*. 2013;34(39):3035-87.
- 16 10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, et al.
17 EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk
18 patients in general practice: cross-sectional survey in 12 European countries. *Eur J*
19 *Cardiovasc Prev Rehabil*. 2010;17(5):530-40.
- 20 11. Alonso-Fernandez M, Mancera-Romero J, Mediavilla-Bravo JJ, Comas-
21 Samper JM, Lopez-Simarro F, Perez-Unanua MP, et al. Glycemic control and use of A1c
22 in primary care patients with type 2 diabetes mellitus. *Prim Care Diabetes*.
23 2015;9(5):385-91.
- 24 12. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective
25 Diabetes Study G. The UKPDS risk engine: a model for the risk of coronary heart disease
26 in Type II diabetes (UKPDS 56). *Clin Sci (Lond)*. 2001;101(6):671-9.
- 27 13. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S,
28 Cederholm J, et al. A new model for 5-year risk of cardiovascular disease in type 2
29 diabetes, from the Swedish National Diabetes Register (NDR). *Diabetes research and*
30 *clinical practice*. 2011;93(2):276-84.
- 31 14. Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure
32 individual vibration thresholds and their variation in 519 non-diabetic subjects. *Br Med J*
33 *(Clin Res Ed)*. 1984;288(6433):1793-5.
- 34 15. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription
35 Registry. *Scand J Public Health*. 2011;39(7 Suppl):38-41.
- 36 16. Sundhedsstyrelsen Center for Evaluering og Medicinsk Teknologivurdering.
37 Type 2-diabetes. Medicinsk teknologivurdering af screening, diagnostik og behandling
38 2003;5(1) [Available from:
39 <https://www.sst.dk/~media/F42943CEAEC743DDAD8CB57FF55C9581.ashx>.
- 40 17. Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving
41 HH, et al. Years of life gained by multifactorial intervention in patients with type 2
42 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised
43 trial. *Diabetologia*. 2016.
- 44 18. Tight blood pressure control and risk of macrovascular and microvascular
45 complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ*.
46 1998;317(7160):703-13.
- 47 19. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A,
48 et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes
49 in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-
50 randomised trial. *Lancet*. 2011;378(9786):156-67.
- 51 20. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The
52 prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes,
53 1988-2010. *Diabetes Care*. 2013;36(8):2271-9.
- 54 21. Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, et
55 al. External validation of the UKPDS risk engine in incident type 2 diabetes: a need for
56 new type 2 diabetes-specific risk equations. *Diabetes Care*. 2014;37(2):537-45.

- 1
2
3 1 22. Wong ND, Patao C, Malik S, Iloeje U. Preventable coronary heart disease
4 2 events from control of cardiovascular risk factors in US adults with diabetes (projections
5 3 from utilizing the UKPDS risk engine). *Am J Cardiol.* 2014;113(8):1356-61.
6 4 23. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et
7 5 al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach.
8 6 Position statement of the American Diabetes Association (ADA) and the European
9 7 Association for the Study of Diabetes (EASD). *Diabetologia.* 2012;55(6):1577-96.
10 8 24. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
11 9 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New*
12 10 *England journal of medicine.* 2015;373(22):2117-28.
13 11 25. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck
14 12 MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *The New England*
15 13 *journal of medicine.* 2016;375(4):311-22.
16 14
17 15
18 16
19 17
20 18

18 **Figure legends**

19 Figure 1 - Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and
20 21 consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1
22 23 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'.
24 25 Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation
26 27 and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit
28 29 with nurse, dietician and endocrinologist. After approximately 8 months patients with no
30 31 complications are referred back to general practice and those with micro- or macrovascular
32 33 complications are referred to the outpatient clinic.
34 35
36 37
38 38
39 39
40 40
41 41
42 42
43 43

44 28 Figure 2 - Proportion of patients achieving the treatment targets for HbA_{1c}, LDL cholesterol,
45 29 systolic and diastolic blood pressure at baseline and at follow-up.
46 30
47 31
48 32

49 30
50 31 Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up. SU,
51 32 sulfonylurea; DPP-4 i, Dipeptidyl peptidase 4 inhibitor; GLP-1, Glucagon-like peptide 1;
52 33 OAD, oral antidiabetic drug; RAS, Renin angiotensin system; ASA, Acetylsalicylic acid
53 34
54 35
55 36
56 37
57 38
58 39
59 40
60 41

Table 1 Baseline characteristics of the study cohort

	N	All	Females (<i>n</i> = 1,732)	Males (<i>n</i> = 2,567)
Age (years)	4,299	59.3 (12.4)	59.9 (12.9)	58.9 (12.1)
Weight (kg)	4,256	91.5 (21.2)	84.4 (20.4)	96.3 (20.4)
Body mass index (kg/m ²)	4,236	31.0 (6.6)	31.8 (7.4)	30.3 (4.4)
Smokers, N (%)	4,071	1,629 (37.9)	622 (35.9)	1,007 (39.5)
Caucasians, N (%)	4,289	3,724 (87)	1,457 (84)	2,267 (89)
Diabetes and complications				
Duration of type 2 diabetes (years)	4,252	7.1 (6.5)	7.3 (6.6)	6.9 (6.5)
GAD65 antibodies ≥25 U/mL, N (%)	2,376	116 (2.7)	59 (3.4)	57 (2.2)
HbA _{1c} (%)	4,253	8.2 (3.9)	8.1 (3.9)	8.2 (19)
HbA _{1c} (mmol/mol)	4,253	66 (19)	65 (19)	66 (19)
Fasting p-glucose (mmol/L)	2,850	9.9 (3.6)	9.6 (3.4)	10.0 (3.7)
Fasting c-peptide (pmol/L) Median (IQR)	2,898	1050 (706-1500)	1050 (699-1517)	1050 (711-1478)
Prior cardiovascular disease, N (%)†	4,299	1,127 (26)	400 (23)	727 (28)
Microalbuminuria, N (%)	4,299	787 (18)	254 (15)	533 (21)
Macroalbuminuria, N (%)	4,299	211 (5)	47 (3)	164 (6)
eGFR (mL/min)	1,335	78 (17)	77 (18)	79 (16)
Simple retinopathy, N (%)	3,859	1134 (29)	422 (27)	712 (31)
Proliferative retinopathy, N (%)	3,859	56 (1)	25 (2)	31 (1)
Peripheral neuropathy, N (%)	2,343	549 (23)	140 (15)	409 (29)
Blood pressure				
Systolic blood pressure (mm Hg)	4,280	141.7 (21.7)	140.5 (22.5)	142.6 (21.1)
Diastolic blood pressure (mm Hg)	4,280	82.5 (11.5)	80.8 (11.4)	83.6 (11.5)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1 Baseline characteristics of the study cohort

	N	All	Females (n = 1,732)	Males (n = 2,567)
Lipids				
Total cholesterol (mmol/L)	3,946	4.7 (1.2)	4.9 (1.3)	4.6 (1.2)
LDL cholesterol (mmol/L)	3,946	2.5 (1.0)	2.6 (1.0)	2.5 (1.0)
HDL cholesterol (mmol/L)	3,946	1.2 (0.4)	1.3 (0.4)	1.2 (0.4)
Triglycerides (mmol/L) Median (IQR)	3,946	1.7 (1.2–2.5)	1.7 (1.2–2.5)	1.7 (1.2-2.6)
Medication				
Metformin, N (%)	4,299	2511 (58)	1025 (59)	1486 (58)
Sulfonylurea, N (%)	4,299	1652 (38)	673 (39)	979 (38)
DPP-4 inhibitor, N (%)	4,299	303 (7)	126 (7)	177 (7)
GLP-1 analog, N (%)	4,299	168 (4)	73 (4)	95 (4)
Insulin, N (%)	4,299	836 (19)	346 (20)	490 (19)
Other OAD, N (%)	4,299	179 (4)	67 (4)	112 (4)
RAS blockade, N (%)	4,299	2027 (47)	736 (17)	1291(30)
All antihypertensive drugs, N (%)	4,299	2678 (62)	1099 (26)	1579 (37)
Lipid lowering drug, N (%)	4,299	1988 (46)	776 (45)	1212 (47)
Acetylsalicylic acid, N (%)	4,299	1538 (36)	530 (31)	1008 (39)

Values are means (SDs) unless stated otherwise.
†Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery, ischaemic heart disease, heart insufficiency, vascular surgery, stroke, transitory cerebral ischaemia, amputation.
CVD, cardiovascular disease; GAD, glutamic acid decarboxylase; HbA_{1c}, haemoglobin A_{1c}; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DPP-4, Dipeptidyl peptidase 4; GLP-1, Glucagon-like peptide 1; OAD, oral antidiabetic drug; RAS, Renin angiotensin system.

Table 2 Estimated CVD or CHD risk

	Baseline	Follow-up
Estimated CVD 5-year risk: NDR Risk engine:		
All	29.8 (19.6-44.6) ^a	25.0 (16.6-37.4) ^{b,*}
F	24.9 (15.9-37.0)	21.1 (13.7-31.1)*
M	34.0 (22.6-48.2)	28.1 (19.1-41.2)*
Estimated CHD 5-year risk: UKPDS Risk Engine:		
All	7.4 (3.9-13.7) ^c	5.0 (2.7-9.2) ^{d,*}
F	4.8 (2.6-8.7)	3.3 (1.9-5.9)*
M	9.6 (5.3-16.7)	6.4 (3.7-11.3)*
Estimated CHD 10-year risk: UKPDS Risk Engine:		
All	17.1 (9.3-30.4) ^c	11.8 (6.5-21.1) ^{d,*}
F	11.4 (6.1-20.0)	7.9 (4.5-14.0)*
M	22.1 (12.6-36.2)	15.0 (9.0-25.4)*

Estimated CVD risk according to the Swedish National Register (NDR) risk engine and the estimated CHD risk according to the UKPDS risk engine. Data is median risk in % (IQR).

a $n = 3,865$; b $n = 3,730$; c $n = 3,895$; d $n = 3,757$, * $P < 0.0001$.




Figure 1 Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'. Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit with nurse, dietician and endocrinologist. After approximately 8 months patients with no complications are referred back to general practice and those with micro- or macrovascular complications are referred to the outpatient clinic.

254x190mm (96 x 96 DPI)




Figure 2 Proportion of patients achieving the treatment targets for HbA1c, LDL cholesterol, systolic and diastolic blood pressure at baseline and at follow-up.

180x171mm (96 x 96 DPI)






Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up. SU, sulfonylurea; DPP-4 inh, Dipeptidyl peptidase 4 inhibitor; GLP-1, Glucagon-like peptide 1; OAD, oral antidiabetic drug; RAS, Renin angiotensin system; ASA, Acetylsalicylic acid

254x190mm (96 x 96 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	21 (Table 1)
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Impact of a multifactorial treatment program on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialized diabetes centre in Denmark

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019214.R1
Article Type:	Research
Date Submitted by the Author:	18-Dec-2017
Complete List of Authors:	Safai, Narges; Steno Diabetes Center Copenhagen, Patient Care Carstensen, Bendix; Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology Vestergaard, Henrik; The Novo Nordisk Foundation, Center for Basic Metabolic Research, Section of Metabolic Genetics; Steno Diabetes Center Copenhagen, Patient Care Ridderstråle, Martin; Novo Nordisk AS; Lunds Universitet, Department of Clinical Sciences
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Diabetes and endocrinology, Medical management
Keywords:	Type 2 diabetes, Glycemic control, Outcomes, CVD risk, Multifactorial treatment

SCHOLARONE™
Manuscripts

only

1
2
3
4 **Title page**

5
6
7 **Impact of a multifactorial treatment program on clinical outcomes and cardiovascular**
8 **risk estimates: a retrospective cohort study from a specialized diabetes centre in**
9 **Denmark**
10
11
12

13
14
15
16 Narges Safai^a, Bendix Carstensen^b, Henrik Vestergaard^c and Martin Ridderstråle^d

17
18 ^a Steno Diabetes Center Copenhagen, Gentofte, Denmark; narges.safai@regionh.dk

19
20 ^b Steno Diabetes Center Copenhagen, Gentofte, Denmark; bendix.carstensen@regionh.dk

21
22 ^c Novo Nordisk Foundation of Basic Metabolic Research, University of Copenhagen,
23
24 Denmark; Henrik.vestergaard@sund.ku.dk

25
26 ^d Novo Nordisk A/S, Søborg, Denmark and Department of Clinical Sciences, Lund
27
28 University, Malmö, Sweden; mtrd@novonordisk.com
29

30
31
32
33 Corresponding author:

34
35 Narges Safai, MD

36
37 Steno Diabetes Center Copenhagen

38
39 Niels Steensens Vej 2-4

40
41 DK-2820 Gentofte

42
43 Denmark

44
45 +45 3091 3395 (direct)

46
47
48 narges.safai@regionh.dk

49
50 Number of tables: 2

51
52 Number of figures: 3

53
54
55
56
57
58
59
60

1
2
3 **1 Abstract**

4 **2 Objectives:** To investigate the impact of a multifactorial treatment program in a real-life

5
6 3 setting on clinical outcomes and estimated cardiovascular disease (CVD) risk.

7
8 4 **Design:** A retrospective observational cohort study, using data from the electronic medical

9
10 5 records and national registers.

11
12 6 **Setting:** Tertiary diabetes centre in Denmark.

13
14 7 **Participants:** Patients with type 2 diabetes ($n=4,299$) referred to a program with focus on

15
16 8 treatment of hyperglycaemia, hypertension and dyslipidaemia, between Jan 1st 2001 and

17
18 9 April 1st 2016.

19
20
21 10 **Outcomes:** Primary outcomes were changes in HbA_{1c}, blood pressure and LDL cholesterol

22
23 11 as well as proportion reaching treatment targets, together with changes in antidiabetic,

24
25 12 antihypertensive and lipid lowering treatment. Our secondary outcome was to investigate the

26
27 13 impact on estimated CVD risk. Linear mixed model for repeated measurements were used for

28
29 14 continuous variables and logistic regression for dichotomous variables.

30
31 15 **Results:** The patients achieved a mean \pm SD decrease in HbA_{1c}, systolic and diastolic blood

32
33 16 pressure (BP), and LDL cholesterol of $1.0\pm 0.04\%$ (10.6 ± 0.4 mmol/mol), 6.3 ± 0.4 mmHg,

34
35 17 2.7 ± 0.2 mmHg and 0.32 ± 0.02 mmol/l, respectively ($p<0.0001$). The proportion of patients

36
37 18 who met the treatment goal for HbA_{1c} ($<7\%$ [<53 mmol/mol]) increased from 31% to 58% (p

38
39 19 <0.0001); for BP ($<130/80$ mm Hg) from 24% to 34% ($p <0.0001$), and for LDL cholesterol

40
41 20 (<2.5 mmol/l (patients without previous CVD) or <1.8 mmol/l (patients with previous CVD))

42
43 21 from 52% to 65%. Those reaching all three guideline treatment targets increased from 4% to

44
45 22 15% ($p<0.0001$), and when relaxing the BP target to $<140/85$ from 8% to 24%. The estimated

46
47 23 CVD risk was relatively reduced by 15.2% using the Swedish National Diabetes Register

48
49 24 Risk Engine and 30.9% using the UKPDS risk engine.

1
2
3 1 **Conclusions:** Our data supports that short term multifactorial treatment of patients with
4
5 2 glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and
6
7 3 associated with a clinically meaningful improvement in CVD risk.
8
9 4
10
11 5
12

13 6 **Strengths and limitations of this study**

- 15
16 7 • Large cohort of dysregulated patients with type 2 diabetes under real-world conditions
17
18 8 and strong validity of data with repeated recordings of clinical measurements and
19
20 9 access to national registries.
21
22 10 • Selection bias in terms of more motivated and high risk patients being referred to the
23
24 11 clinic, and by exclusion of those who did not show up.
25
26 12 • The use of risk engines can only give an estimate of the CVD risk and the UKPDS
27
28 13 risk engine is based on a population many years prior to ours where treatment
29
30 14 guidelines were different.
31
32

33 15
34
35 16 **Keywords:** Type 2 diabetes, glycaemic control, outcomes, CVD risk and multifactorial
36
37 17 treatment
38
39
40 18
41
42 19
43
44 20
45
46 21
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Introduction**

2 Type 2 diabetes is an increasing global health threat. It is estimated that 439 million people
3 will be diagnosed with diabetes by 2030 (1). Type 2 diabetes is associated with an increased
4 risk of microvascular complications such as nephropathy, neuropathy, and retinopathy as well
5 as macrovascular disease, resulting in a decreased life expectancy and substantial personal
6 and societal expenses (2). Ensuring good glycaemic control remains the most effective
7 therapeutic measure to reduce the risk of developing microvascular disease (3, 4).

8 Multifactorial treatment with tight control of glycaemia, blood pressure (BP) and lipids,
9 accompanied by acetylsalicylic acid and lifestyle advice, is known to reduce progression of
10 microvascular complications, cardiovascular disease (CVD), and mortality by 50% in patients
11 with type 2 diabetes and microalbuminuria (5-7). Consequently, diabetes guidelines have
12 advocated an intensified treatment approach aiming at addressing and reducing all CVD risk
13 factors in patients with diabetes since several years (8, 9).

14
15 For most patients, sufficient glycaemic, BP and lipid control can be achieved in a primary
16 care setting but in high risk patients, or in patients with complex treatment regimens, the
17 proportion of patients who achieve metabolic control in primary care is lower (10, 11). In this
18 situation, in most health care systems, high risk patients are referred to specialist clinics for
19 evaluation. A broad risk factor intervention in this subgroup has proven particularly effective
20 in the Steno-2 study (5). However, it remains unknown whether the results seen in the study
21 setting can be achieved in clinical practice.

22
23 The overall aim of this study was to describe how the multifactorial intervention methods
24 from the Steno-2 study perform in a larger scale clinical setting. Our primary objective was to
25 describe changes in metabolic outcomes and pharmacological treatment as a result of such

1 structured short term intervention and to test for gender differences. Our secondary objective
2 was to evaluate the impact on estimated CVD risk by using two different risk assessment
3 tools: the UKPDS Risk Engine (12), and the 5-year Swedish National Diabetes Registry
4 (NDR) risk model (13).

6 **Methods**

7 Design and setting

8 This study is based on patients referred to Steno Diabetes Center (SDC), a tertiary
9 multidisciplinary and highly specialized diabetes centre in the Capital Region of Denmark. It
10 serves as one out of three referral centres with a catchment area of over 1.7 million people
11 and provides diabetes care on a permanent basis to about 5.600 patients. During the Steno-2
12 study, SDC designed a treatment program algorithm specifically for patients with type 2
13 diabetes and glycaemic dysregulation. The primary goal of the program is to improve patient
14 quality of life and reduce mortality by prevention of acute and chronic complications of
15 diabetes. This is done by motivating and encouraging self-management, professional support
16 in behavioural changes, and pharmacological treatment according to national and
17 international guidelines. The SDC Type 2 Clinic (T2C) opened in 2001, providing care for
18 patients referred from general practitioners (GPs) or other hospitals in the region. Patients
19 were referred to the clinic either as newly diagnosed with a need for education and start of
20 treatment, requiring a shift to insulin treatment, having micro- or macrovascular
21 complications, or having glycaemic dysregulation in spite of attempts to control the disease
22 by the GP. The program, which is still running and is the same for all patients, involves a
23 consultation with a nurse, a dietician, and a physician in a structured order with specific
24 assignments and is comparable to the intensive treatment arm of the Steno-2 study (Figure 1).
25 The individual visits are, depending on the need, complemented by optional group-based

1 theme sessions with the overall aim of facilitating patient empowerment and with phone
2 consultations from a nurse. The treatment program consist of self-management training with
3 a focus on knowledge, lifestyle behaviour including diet, physical activity and smoking
4 cessation, skills to improve glycaemic control such as self-monitoring of blood glucose and
5 skills to prevent and identify complications. Furthermore, there is focus on pharmacological
6 treatment of hyperglycaemia, hypertension and dyslipidaemia. After approximately eight
7 months, patients were evaluated for referral back to their GP, or to continue at the SDC
8 outpatient clinic. The structure of program has remained unchanged in the study period while
9 e.g. medications used have followed updated treatment guidelines. The Danish treatment
10 guidelines have followed the international guidelines from EASD and ADA and were revised
11 in 2003, 2011 and 2014 (14-16). We defined the baseline and evaluation follow-up visits as
12 the first and last visit to the T2C, respectively. This study is a retrospective observational
13 study with demographics, clinical, and laboratory information extracted from the electronic
14 medical records and laboratory database of SDC.

15 16 Study population

17 We included all patients who had finalized a treatment program between 1st of January 2001
18 and 1st of April 2016 ($n = 4,489$), and to avoid no-shows, once off or very brief consultations
19 we excluded patients with a treatment duration under 30 days (i.e. between the baseline and
20 follow-up visits, $n = 190$). We ended up with a total of $n = 4,299$ patients. 16% of the patients
21 were subsequently re-referred to the clinic, but we only included their first treatment program
22 here.

23 24 Subject characteristics

1
2
3 1 Laboratory analyses at the baseline visit were encouraged to be fasting and included: glucose,
4
5 2 HbA_{1c}, haemoglobin, creatinine, total-cholesterol, high-density lipoprotein-cholesterol (HDL)
6
7 3 cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides (TG), C-peptide and
8
9 4 urine albumin. At all in-between visits and at follow-up an HbA_{1c}, BP and weight were
10
11 5 measured. All laboratory and anthropometric measurements were recorded using
12
13 6 standardized procedures at the SDC accredited laboratory (ISO 15189). Body mass index
14
15 7 (BMI) was calculated from weight and height (kg/m²). A person was considered overweight
16
17 8 at BMI \geq 25 kg/m², and obese at BMI \geq 30 kg/m². For BP and heart rate automated
18
19 9 oscillometric blood pressure recorders were used (AND UA-787plus, A&D medical,
20
21 10 California, USA). Smoking status was obtained at every visit.
22
23
24
25

26 12 Diabetes complications and pharmacological treatment

27
28 13 Micro albuminuria was here defined as a morning urine sample with urine albumin of 30-300
29
30 14 mg/L or urine albumin to creatinine ratio $>$ 30 mg/g to 300 mg/g at the first visit. Macro
31
32 15 albuminuria likewise but with a value $>$ 300 mg/L or $>$ 300 mg/g. Peripheral neuropathy was
33
34 16 defined by examining vibration sensation with a biothesiometer and using an age-adjusted
35
36 17 threshold (17). Information on cardiovascular disease was obtained from The National Patient
37
38 18 Register and included diagnosis from 1977 till 2015 and procedures from 1995 till 2015.
39
40

41 19 Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery,
42
43 20 ischaemic heart disease, heart insufficiency, atrial fibrillation, vascular surgery, stroke,
44
45 21 transitory cerebral ischaemia and amputations using ICD-8 and ICD-10 codes.
46
47

48 22 Information on medication was obtained by Register of Medicinal Products Statistics, where
49
50 23 individual-level data on all prescription drugs sold in Danish community pharmacies since
51
52 24 1994 has been recorded and administered by Statistics Denmark (18). A person was defined
53
54 25 as being on a treatment at baseline if they had purchased a prescribed drug less than 180 days
55
56
57
58
59
60

1 before their first visit and at follow-up if they purchased a prescribed drug after their first
2 visit and less than 30 days after their last visit.

3 Permission to use data from the patient register was obtained from the Danish Data Protection
4 Agency (ref. number: 2007-58-0015) and from the Danish Patient Safety Authority.

5 6 CVD risk

7 To evaluate the effect of changes in metabolic outcomes on the estimated risk of CVD, we
8 calculated CVD risk at baseline and at follow-up using two different risk assessment tools: a
9 Swedish risk model specific for type 2 diabetes (13) and the UKPDS Risk Engine (12). The
10 Swedish model is based on patients with type 2 diabetes using 12 predictors: sex, age,
11 diabetes duration, TG, HDL cholesterol, HbA_{1c}, systolic BP, BMI, smoking status,
12 albuminuria, atrial fibrillation and previous CVD. It is derived from a large observational
13 sample of patients ($n = 24,288$) in the Swedish National Diabetes Register (NDR) followed
14 from 2002 to 2007 and estimates the 5-year risk of CVD. The UKPDS Risk Engine is also
15 type 2 diabetes-specific and based on 4,540 patients from the UKPDS trial (1977 to 1991). It
16 includes HbA_{1c} as a continuous variable and calculates the risk of developing a new coronary
17 heart disease (CHD) event.

18 19 Statistical methods

20 The primary outcomes were changes in blood glucose control (HbA_{1c}), BP and lipids from
21 first visit (baseline) to end of treatment (follow-up evaluation visit) and to explore gender
22 differences in outcomes. Furthermore we investigated how many patients reached the
23 recommended targets for HbA_{1c} (A), BP (B) and LDL cholesterol (C) according to national
24 guidelines (14), collectively referred to as ABC control: HbA_{1c} < 7% (< 53 mmol/mol), BP <
25 130/80 mm Hg and LDL cholesterol < 2.5 mmol/l (< 100 mg/dl, patients without previous

1
2
3 1 CVD) or < 1.8 mmol/l (< 70 mg/dl, patients with previous CVD). For blood lipids, the T2C
4
5 2 program assumed they would not deteriorate if they were on target at baseline and
6
7 3 measurements were only repeated in case they were not at target at baseline. Accordingly, for
8
9 4 this analysis a last observation carried forward approach was used to impute missing data. *T*
10
11 5 test was used for gender differences at baseline and at follow-up. Comparison between
12
13 6 baseline and follow-up was made using mixed model for repeated measurements (MMRM)
14
15 7 for continuous variables with the subject as a random effect and logistic regression for
16
17 8 dichotomous variables e.g. pharmacological treatment. McNemar test was used to compare
18
19 9 changes in categorical variables. For risk estimates, exact 95%-confidence intervals (CI) were
20
21 10 calculated. SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC) was used for database
22
23 11 management and all of the above-mentioned analyses.
24
25
26
27
28

29 13 **Results**

30 31 14 32 33 15 Study cohort characteristics

34
35 16 Baseline characteristics of the study cohort are shown in Table 1. The majority of patients
36
37 17 were Caucasians, and 19% were diagnosed with diabetes within a year before their referral.
38
39 18 There were more males ($n = 2,567$) than females ($n = 1,732$) but no difference in treatment
40
41 19 duration: median treatment program duration was 8.4 months (IQR: 6.1, 11.3). There were
42
43 20 more male smokers and ex-smokers. Males had a higher level of HbA_{1c}, BP, weight and TG
44
45 21 but lower BMI and cholesterol levels at baseline (Table 1).
46
47
48
49

50 23 Metabolic outcomes

51
52 24 There was a significant decrease in HbA_{1c} between baseline and follow-up of $1.0 \pm 0.04\%$
53
54 25 (10.6 ± 0.4 mmol/mol), with no gender difference. The decrease in systolic BP was 6.3 ± 0.4
55
56
57
58
59

1 mm Hg and in diastolic BP 2.7 ± 0.2 mm Hg ($p < 0.0001$ for both). The effect of treatment on BP was the same in both genders. There was a significant decrease in total-cholesterol, LDL and TG of 0.39 ± 0.03 mmol/l, 0.32 ± 0.02 mmol/l and 0.22 ± 0.05 mmol/l, respectively. There was no change in HDL levels overall ($p = 0.2$). As expected, females had higher HDL levels than males, both at baseline and at follow-up ($p < 0.0001$). This gender difference was also seen for total- and LDL cholesterol levels where females had higher levels at both baseline and follow-up. The effect of treatment on lipid levels was equal in both genders.

9 ABC control

10 In general, the proportion of patients achieving full ABC control according to national guideline treatment targets increased from 4% to 15% ($p < 0.0001$). More females were achieving all three treatment targets at both baseline ($p = 0.047$) and at follow-up ($p = 0.014$). Patients achieving the HbA_{1c} target increased from 31% to 58% ($p < 0.0001$), the BP target from 24% to 34% ($p < 0.0001$), and the LDL target from 52% to 65% ($p = 0.002$, Figure 2). If the BP target was relaxed from $< 130/80$ mm Hg to $< 140/85$ mm Hg the percentage achieving the BP target increased from 43% at baseline to 58% at follow-up ($p < 0.0001$), and consequently full ABC control from 8% at baseline to 24% at follow-up ($p < 0.0001$).

19 Changes in pharmacological treatment

20 The most common antidiabetic drug at baseline was metformin, which 58.4% of the patients were on, followed by sulphonyl urea (SU), 38.4%, and insulin, 19.5% (Figure 3). Only a small proportion of patients were on dipeptidyl peptidase 4 (DPP-4) inhibitors, 7.0%, glucagon-like peptide 1 (GLP-1) analogues, 3.9%, or other antidiabetic drug, 4.2%. In general there was an increase in the use of medication during the program. The largest increase was seen in use of metformin to 75.3%, insulin to 36.9% and GLP1-analogues to

1 11.6%. While SU only increased slightly to 41.8%, DPP-4 inhibitors to 9.6% and other
2 antidiabetics 4.3%.

3 As part of the multifactorial treatment program, we also observed an increase in use of
4 antihypertensive drugs to 75.3%, lipid lowering drugs to 75.9% and acetylsalicylic acid
5 (ASA) to 69.6%.

6 7 Changes in cardiovascular risk

8 Estimated baseline and follow-up cardiovascular risk according to the used risk engines are
9 shown in Table 2. Using the Swedish NDR model which predicts the 5 year risk of a new
10 CVD event in a diabetic population, we observed a relative risk reduction of 15.2% (95% CI:
11 14.5-15.9). The UKPDS risk engine showed a relative risk reduction of 30.9% (95% CI:
12 30.3-31.5) in the 5 year CHD risk estimate. Females had a lower risk than males both at
13 baseline and at follow-up according to both risk models ($p < 0.0001$). Meanwhile, both
14 according to the Swedish NDR model and the UKPDS risk engine, females had a smaller
15 relative risk reduction compared to males ($p < 0.0001$).

16 17 **Discussion**

18
19 This study shows that a short term targeted multifactorial treatment program in a specialized
20 clinical setting can improve metabolic outcome measures and CVD risk in patients with type
21 2 diabetes and high prevalence of complications. This confirms that multifactorial treatment
22 not only works in a clinical study setting, but is also feasible and effective in real world
23 clinical practice. With a specialized group of health care providers and a structured treatment
24 and educational program that focuses on lifestyle intervention, self-management training and

1 pharmacological treatment of hyperglycaemia, hypertension and dyslipidaemia, it is possible
2 to accomplish significant CVD risk reductions in a high risk population with diabetes.

3 4 ABC control

5 Intensive multifactorial intervention in high risk patients has previously been shown to reduce
6 CVD and mortality (7), and a recent 21 years follow-up of the Steno-2 study population
7 shows that patients in the intensive-therapy group survived for a median of 7.9 years longer
8 than the conventional-therapy group patients (19). Here we show that the same treatment
9 program also works in clinical practice in a more diverse population, and results in a
10 substantial reduction of 5- and 10-year CVD risk as estimated by two of the available and
11 commonly used risk engines. In terms of risk factor intervention, glucose control continuous
12 to be the greatest challenge to diabetes care. Nonetheless, all but 21% of patients changed
13 from a higher to a lower HbA_{1c} category in this follow-up. Importantly, the improvement in
14 glycaemic control was not accompanied by a general increase in weight. In fact, although we
15 found that 15% of those in the normal weight category shifted to the overweight category
16 when comparing the changes in BMI categories, 15% of those who were in the obese or
17 overweight category dropped to a lower weight category. The weight gain observed in some
18 patients is probably explained by the increased use of insulin, while weight loss in others can
19 be explained by an increased use of GLP-1 receptor agonist treatment in recent years along
20 with lifestyle management including dietary and physical activity advice.

21
22 With focus on hyperglycaemia, hypertension and dyslipidaemia, we found an increase in the
23 proportion of patients achieving the recommended targets that are comparable to intervention
24 studies (20, 21). Here, the relative proportion of patients achieving HbA_{1c} < 53 mmol/mol
25 (7%) nearly doubled, BP < 130/80 mm Hg increased by 42% and LDL < 2.5 mmol/l by 25%.

1
2
3 1 The T2C treatment program in this complex high-risk cohort resulted in a higher prevalence
4
5 2 of risk factors in control equal to what has been observed in the more general diabetes
6
7 3 population in the National Health and Nutrition Examination Surveys (NHANES) from 2007
8
9 4 to 2010 (22). The NHANES data differ in the way that their data was cross-sectional with
10
11 5 participants with self-reported diabetes, without any distinction between type 1 and type 2,
12
13 6 and with a different risk profile. Our population was more selected by being referred from
14
15 7 their GP and requiring specialized care, which means they either had more comorbidities or a
16
17 8 more complex treatment than the general patient with type 2 diabetes. For HbA_{1c} 58% in our
18
19 9 cohort achieved the treatment target vs 53% in the NHANES cohort and for LDL-cholesterol
20
21 10 65% vs 56%, respectively. But for BP there was a big difference, 34% in our cohort vs. 51%
22
23 11 in the NHANES cohort. This could be due to a higher prevalence of high BP in this group of
24
25 12 patients selected with complex disease and long diabetes duration. We did observe a time
26
27 13 trend in the data as the proportion of patients achieving the stringent BP target increased from
28
29 14 23% in 2001 to 44% in 2015. The same improvement trend over time was observed in the
30
31 15 proportion of patients achieving all three ABC targets; 7% in 2001 increasing to an average
32
33 16 of 16% from 2006 and forward in our material and in the NHANES data from 7% in 1999-
34
35 17 2002 to 19% in 2007-2010.
36
37
38
39
40
41
42

19 CVD risk

43
44 20 To estimate the CVD risk in patients with type 2 diabetes is helpful to follow-up on treatment
45
46 21 and to target further measures to patients at risk. In this study we used two different CVD risk
47
48 22 engines to estimate the effect of the treatment program. The UKPDS risk engine is diabetes-
49
50 23 specific and has several advantages as it incorporates HbA_{1c} and diabetes duration as
51
52 24 continuous variables (12). However, it is still not ideal as it is based on the patients recruited
53
54 25 by UKPDS for randomization in a clinical trial two decades ago before newer and more
55
56
57
58
59
60

1
2
3 1 effective treatments were available or widely used (e.g. statins, angiotensin converting
4
5 2 enzyme inhibitors and antidiabetic drugs). Accordingly, recent validation showed poor
6
7 3 calibration and overestimation of the CHD risk (23). A model that seems more suitable for
8
9 4 our population is the Swedish NDR risk model, which is based on a more recent and
10
11 5 nationwide population, reflecting a more diverse population and taking into account the
12
13 6 history of previous CVD and BMI. By using this model we found a relative reduction in the
14
15 7 estimated 5-year CVD risk of 16%, after approximately eight months, despite the increase in
16
17 8 age and diabetes duration. Notably, the fact that 26% of the patients had a prior CVD
18
19 9 diagnosis at baseline reflects the high risk profile and complexity of the population that was
20
21 10 referred to the treatment program. This of course does not normalise their actual risk, which
22
23 11 will still be high, but can be a motivating factor for the patients that there are some
24
25 12 modifiable risk factors that can reduce their risk. In comparison, the population used in the
26
27 13 Swedish model had a mean risk of 11.9% and a 5-year risk of fatal/non-fatal CVD of more
28
29 14 than 10% is defined as high risk. According to this 92% of our population was in high risk at
30
31 15 baseline. The UKPDS risk engine which estimates the risk of the first CHD event in 5 or 10
32
33 16 years, gives a lower 5 and 10 year risk estimate at baseline than the Swedish model, 7.4% and
34
35 17 17.1% respectively. This is nearly the same as the 10-year risk found in a NHANES
36
37 18 population from 2007 to 2012 of 16.5% if no risk factors were in control and 10.2% if all risk
38
39 19 factors were in control when using the same risk engine (24).

40
41
42 20 Interestingly, both the NDR and UKPDS risk engines estimated a higher risk reduction in
43
44 21 males than in females. This, perhaps expected finding, can be due to a relatively greater
45
46 22 HbA_{1c} reduction seen in males, which is used in both the NDR and the UKPDS risk engines.
47
48 23 However, this alone could not explain the whole difference, as the gender difference
49
50 24 remained significant after excluding HbA_{1c} from the equation. This in spite a higher
51
52 25 percentage of females achieved the metabolic targets.
53
54
55
56
57
58
59
60

1
2
3 14
5 2 Strengths and limitations

6
7 3 Strengths of this study include the validity of data with repeated recordings of the HbA_{1c} and
8
9 4 BP at each visit, and that it includes a large cohort of patients treated under real-life
10
11 5 conditions such that results might have greater external validity than the highly selected
12
13 6 populations in randomized controlled trials (RCT). Still, we cannot rule out that there might
14
15 7 be a selection bias in terms of more motivated patients being referred to the clinic, and by
16
17 8 exclusion of those who did not show up.

19
20 9 As a result of using a database and a register, we do not have complete data on all patients
21
22 10 and therefore the cohort size changes a bit as results are based on those without missing
23
24 11 values. Another limitation is that there is a lack of patient reported outcomes, such as adverse
25
26 12 events of drugs and general well-being. This was not possible to extract from the electronic
27
28 13 medical records. Furthermore we cannot be sure that the patients going through a treatment
29
30 14 program actually completed the program or was discharged for other reasons. It is also
31
32 15 important to acknowledge that most of the treatment programs analysed here were completed
33
34 16 before many of the new anti-diabetic treatments, as GLP1-analogs and sodium-glucose co-
35
36 17 transporter 2 (SGLT2)-inhibitors, were widely used and before acceptance of a more
37
38 18 personalized treatment as recommended in the position statement from ADA and EASD in
39
40 19 2012 (16). Another limitation of this study is the use of risk engines that only give an
41
42 20 estimate of the CVD or CHD risk and that UKPDS is based on a population many years prior
43
44 21 to ours and treatment guidelines were not the same.

45
46 22 Meanwhile, the data serves as a baseline benchmark for real world data studies as to what can
47
48 23 be achieved in routine clinical practice before these treatments and guidelines get wider use
49
50 24 and implementation. The use of a more individualized treatment approach with involvement
51
52 25 of the patient in decision making is increasingly used in the treatment programs at the

1 moment and is expected to increase adherence to therapy. Furthermore, the combination of a
2 more individualized HbA_{1c} target and a broader selection of antidiabetic, antihypertensive
3 and dyslipidaemia treatment will likely increase the proportion of patients achieving their
4 treatment goals and thereby reduce their CVD risk and mortality. Specifically, since the
5 EMPA-REG OUTCOME trial showed a 38% and the LEADER trial a 22% relative risk
6 reduction in deaths from CVD events in patients with type 2 diabetes and a high risk of
7 cardiovascular events (25, 26), this gives us further treatment options in this patient group.
8 Therefore constant evaluation of the effects of our treatments on the risk of CVD or mortality
9 is necessary. Combining these drugs, the treatment program evaluated here, and an
10 individualized approach would be a logical next step for future studies.

12 Conclusion

13 This study of patients with type 2 diabetes who undergo structured treatment program lasting
14 less than one year show that it is possible to increase the proportion of patients achieving the
15 target levels for HbA_{1c}, BP, and LDL, thereby reducing their estimated CVD and CHD risk.
16 To the strengths of such a structured program we count the focus on treatment targets by a
17 multidisciplinary team and the fact that it is time limited, which reduces clinical inertia and
18 costs. Our results show that intensive treatment is not only effective in the RCT setting, but
19 also in clinical practice and should encourage other health care systems to establish similar
20 programs.

1
2
3 14
5 2 **Conflicts of interest**

6
7 3 NS, BC and HV were employed at Steno Diabetes Center A/S, now known as Steno Diabetes
8
9 4 Center Copenhagen and MR was employed there when the study was initiated. Steno
10
11 5 Diabetes Center A/S was a research hospital working in the Danish National Health Service
12
13 6 and owned by Novo Nordisk A/S. NS and BC own shares in Novo Nordisk A/S.

14
15
16 7 **Funding**

17
18 8 This study has been funded by Innovation Fund Denmark

19
20 9 **Contribution statement**

21
22 10 NS and BC were responsible for data management and statistical analysis. NS and MR were
23
24 11 responsible for interpretation of data and writing of the article. HV was responsible
25
26 12 interpretation and critical revision of the article. All authors fully approved the final version
27
28 13 of the article.

29
30
31 14 **Data sharing statement**

32
33 15 Clinical data will be available at request, but information on diagnosis and medication is not
34
35 16 allowed to be shared by the Danish National Patient Register or Statistics Denmark.

36
37
38
39
40 18 **Uncategorized References**

- 41 19 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE.
42 20 Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes*
43 21 *research and clinical practice*. 2014;103(2):137-49.
44 22 2. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et
45 23 al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a
46 24 collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-
47 25 22.
48 26 3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of
49 27 intensive glucose control in type 2 diabetes. *The New England journal of medicine*.
50 28 2008;359(15):1577-89.
51 29 4. UKPDS. Effect of intensive blood-glucose control with metformin on
52 30 complications in overweight patients with type 2 diabetes (UKPDS 34). *UK Prospective*
53 31 *Diabetes Study (UKPDS) Group. Lancet*. 1998;352(9131):854-65.
54 32 5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
55 33 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
56 34 *The New England journal of medicine*. 2003;348(5):383-93.

- 1 6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin
2 compared with conventional treatment and risk of complications in patients with type 2
3 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*.
4 1998;352(9131):837-53.
- 5 7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a
6 multifactorial intervention on mortality in type 2 diabetes. *The New England journal of*
7 *medicine*. 2008;358(6):580-91.
- 8 8. IDF Clinical Guidelines Task Force. Global guideline for Type 2
9 diabetes. . Brussels: International Diabetes Federation; 2005.
- 10 9. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F,
11 et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed
12 in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and
13 cardiovascular diseases of the European Society of Cardiology (ESC) and developed in
14 collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart*
15 *J*. 2013;34(39):3035-87.
- 16 10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, et al.
17 EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk
18 patients in general practice: cross-sectional survey in 12 European countries. *Eur J*
19 *Cardiovasc Prev Rehabil*. 2010;17(5):530-40.
- 20 11. Alonso-Fernandez M, Mancera-Romero J, Mediavilla-Bravo JJ, Comas-
21 Samper JM, Lopez-Simarro F, Perez-Unanua MP, et al. Glycemic control and use of A1c
22 in primary care patients with type 2 diabetes mellitus. *Prim Care Diabetes*.
23 2015;9(5):385-91.
- 24 12. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective
25 Diabetes Study G. The UKPDS risk engine: a model for the risk of coronary heart disease
26 in Type II diabetes (UKPDS 56). *Clin Sci (Lond)*. 2001;101(6):671-9.
- 27 13. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S,
28 Cederholm J, et al. A new model for 5-year risk of cardiovascular disease in type 2
29 diabetes, from the Swedish National Diabetes Register (NDR). *Diabetes research and*
30 *clinical practice*. 2011;93(2):276-84.
- 31 14. Sundhedsstyrelsen CfEoMT. Type 2-diabetes. Medicinsk teknologivurdering
32 af screening, diagnostik og behandling 2003 [Available from:
33 <https://www.sst.dk/~media/F42943CEAEC743DDAD8CB57FF55C9581.ashx>.
34
- 35 15. Snorgaard O DT, Breum L et al. Farmakologisk behandling af type 2-
36 diabetes – mål og algoritmer - 2014 2014 [Available from:
37 <http://www.endocrinology.dk/PDF/FarmakologiskbehandlingDM2rev2014.pdf>.
38
- 39 16. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et
40 al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach.
41 Position statement of the American Diabetes Association (ADA) and the European
42 Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55(6):1577-96.
- 43 17. Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure
44 individual vibration thresholds and their variation in 519 non-diabetic subjects. *Br Med J*
45 *(Clin Res Ed)*. 1984;288(6433):1793-5.
- 46 18. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription
47 Registry. *Scand J Public Health*. 2011;39(7 Suppl):38-41.
- 48 19. Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving
49 HH, et al. Years of life gained by multifactorial intervention in patients with type 2
50 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised
51 trial. *Diabetologia*. 2016.
- 52 20. Tight blood pressure control and risk of macrovascular and microvascular
53 complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ*.
54 1998;317(7160):703-13.
- 55 21. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A,
56 et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes
in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-
randomised trial. *Lancet*. 2011;378(9786):156-67.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. *Diabetes Care*. 2013;36(8):2271-9.
23. Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, et al. External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations. *Diabetes Care*. 2014;37(2):537-45.
24. Wong ND, Patao C, Malik S, Iloeje U. Preventable coronary heart disease events from control of cardiovascular risk factors in US adults with diabetes (projections from utilizing the UKPDS risk engine). *Am J Cardiol*. 2014;113(8):1356-61.
25. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New England journal of medicine*. 2015;373(22):2117-28.
26. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *The New England journal of medicine*. 2016;375(4):311-22.

Figure legends

Figure 1 - Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'. Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit with nurse, dietician and endocrinologist. After approximately 8 months patients with no complications are referred back to general practice and those with micro- or macrovascular complications are referred to the outpatient clinic.

Figure 2 - Proportion of patients achieving the treatment targets for HbA_{1c}, LDL cholesterol, systolic and diastolic blood pressure at baseline and at follow-up.

Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up.

Table 1 Baseline characteristics of the study cohort

	N	All	Females (<i>n</i> = 1,732)	Males (<i>n</i> = 2,567)
Age (years)	4,299	59.3 (12.4)	59.9 (12.9)	58.9 (12.1)
Weight (kg)	4,256	91.5 (21.2)	84.4 (20.4)	96.3 (20.4)
Body mass index (kg/m ²)	4,236	31.0 (6.6)	31.8 (7.4)	30.3 (4.4)
Smokers, N (%)	4,071	1,629 (37.9)	622 (35.9)	1,007 (39.5)
Caucasians, N (%)	4,289	3,724 (87)	1,457 (84)	2,267 (89)
Diabetes and complications				
Duration of type 2 diabetes (years)	4,252	7.1 (6.5)	7.3 (6.6)	6.9 (6.5)
Diabetes duration < 1 year, N (%)	4,252	828 (19.5)	311 (18.1)	517 (20.4)
GAD65 antibodies ≥25 U/mL, N (%)	2,376	116 (2.7)	59 (3.4)	57 (2.2)
HbA _{1c} (%)	4,253	8.2 (3.9)	8.1 (3.9)	8.2 (19)
HbA _{1c} (mmol/mol)	4,253	66 (19)	65 (19)	66 (19)
Fasting p-glucose (mmol/L)	2,850	9.9 (3.6)	9.6 (3.4)	10.0 (3.7)
Fasting c-peptide (pmol/L) Median (IQR)	2,898	1050 (706-1500)	1050 (699-1517)	1050 (711-1478)
Prior cardiovascular disease, N (%)†	4,299	1,127 (26)	400 (23)	727 (28)
Microalbuminuria, N (%)	4,299	787 (18)	254 (15)	533 (21)
Macroalbuminuria, N (%)	4,299	211 (5)	47 (3)	164 (6)
eGFR (mL/min)	1,335	78 (17)	77 (18)	79 (16)
Simple retinopathy, N (%)	3,859	1134 (29)	422 (27)	712 (31)
Proliferative retinopathy, N (%)	3,859	56 (1)	25 (2)	31 (1)
Peripheral neuropathy, N (%)	2,343	549 (23)	140 (15)	409 (29)
Blood pressure				
Systolic blood pressure (mm Hg)	4,280	141.7 (21.7)	140.5 (22.5)	142.6 (21.1)

Table 1 Baseline characteristics of the study cohort

	N	All	Females (<i>n</i> = 1,732)	Males (<i>n</i> = 2,567)
Diastolic blood pressure (mm Hg)	4,280	82.5 (11.5)	80.8 (11.4)	83.6 (11.5)
Lipids				
Total cholesterol (mmol/L)	3,946	4.7 (1.2)	4.9 (1.3)	4.6 (1.2)
LDL cholesterol (mmol/L)	3,946	2.5 (1.0)	2.6 (1.0)	2.5 (1.0)
HDL cholesterol (mmol/L)	3,946	1.2 (0.4)	1.3 (0.4)	1.2 (0.4)
Triglycerides (mmol/L) Median (IQR)	3,946	1.7 (1.2–2.5)	1.7 (1.2–2.5)	1.7 (1.2–2.6)
Medication				
Metformin, N (%)	4,299	2511 (58)	1025 (59)	1486 (58)
Sulfonylurea, N (%)	4,299	1652 (38)	673 (39)	979 (38)
DPP-4 inhibitor, N (%)	4,299	303 (7)	126 (7)	177 (7)
GLP-1 analogue, N (%)	4,299	168 (4)	73 (4)	95 (4)
Insulin, N (%)	4,299	836 (19)	346 (20)	490 (19)
Other OAD, N (%)	4,299	179 (4)	67 (4)	112 (4)
RAS blockade, N (%)	4,299	2027 (47)	736 (17)	1291(30)
All antihypertensive drugs, N (%)	4,299	2678 (62)	1099 (26)	1579 (37)
Lipid lowering drug, N (%)	4,299	1988 (46)	776 (45)	1212 (47)
Acetylsalicylic acid, N (%)	4,299	1538 (36)	530 (31)	1008 (39)

Values are means (SDs) unless stated otherwise.

†Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery, ischaemic heart disease, heart insufficiency, vascular surgery, stroke, transitory cerebral ischaemia, amputation.

CVD, cardiovascular disease; GAD, glutamic acid decarboxylase; HbA_{1c}, haemoglobin A_{1c}; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DPP-4, Dipeptidyl peptidase 4; GLP-1, Glucagon-like peptide 1; OAD, oral antidiabetic drug; RAS, Renin angiotensin system.

Table 2 Estimated CVD or CHD risk

	Baseline	Follow-up
Estimated CVD 5-year risk: NDR Risk engine:		
All	29.8 (19.6-44.6) ^a	25.0 (16.6-37.4) ^{b,*}
F	24.9 (15.9-37.0)	21.1 (13.7-31.1)*
M	34.0 (22.6-48.2)	28.1 (19.1-41.2)*
Estimated CHD 5-year risk: UKPDS Risk Engine:		
All	7.4 (3.9-13.7) ^c	5.0 (2.7-9.2) ^{d,*}
F	4.8 (2.6-8.7)	3.3 (1.9-5.9)*
M	9.6 (5.3-16.7)	6.4 (3.7-11.3)*
Estimated CHD 10-year risk: UKPDS Risk Engine:		
All	17.1 (9.3-30.4) ^c	11.8 (6.5-21.1) ^{d,*}
F	11.4 (6.1-20.0)	7.9 (4.5-14.0)*
M	22.1 (12.6-36.2)	15.0 (9.0-25.4)*

Estimated CVD risk according to the Swedish National Register (NDR) risk engine and the estimated CHD risk according to the UKPDS risk engine. Data is median risk in % (IQR).

a $n = 3,865$; b $n = 3,730$; c $n = 3,895$; d $n = 3,757$, * $P < 0.0001$.




Figure 1 - Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'. Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit with nurse, dietician and endocrinologist. After approximately 8 months patients with no complications are referred back to general practice and those with micro- or macrovascular complications are referred to the outpatient clinic.

121x170mm (300 x 300 DPI)




Figure 2 - Proportion of patients achieving the treatment targets for HbA1c, LDL cholesterol, systolic and diastolic blood pressure at baseline and at follow-up.

183x174mm (300 x 300 DPI)






Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up.

156x120mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	21 (Table 1)
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Impact of a multifactorial treatment program on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialized diabetes centre in Denmark

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019214.R2
Article Type:	Research
Date Submitted by the Author:	23-Jan-2018
Complete List of Authors:	Safai, Narges; Steno Diabetes Center Copenhagen, Patient Care Carstensen, Bendix; Steno Diabetes Center Copenhagen, Department of Clinical Epidemiology Vestergaard, Henrik; The Novo Nordisk Foundation, Center for Basic Metabolic Research, Section of Metabolic Genetics; Steno Diabetes Center Copenhagen, Patient Care Ridderstråle, Martin; Novo Nordisk AS; Lunds Universitet, Department of Clinical Sciences
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Diabetes and endocrinology, Medical management
Keywords:	Type 2 diabetes, Glycemic control, Outcomes, CVD risk, Multifactorial treatment

SCHOLARONE™
Manuscripts

only

1
2
3
4 **Title page**

5
6
7 **Impact of a multifactorial treatment program on clinical outcomes and cardiovascular**
8 **risk estimates: a retrospective cohort study from a specialized diabetes centre in**
9 **Denmark**
10
11
12

13
14
15
16 Narges Safai^a, Bendix Carstensen^b, Henrik Vestergaard^c and Martin Ridderstråle^d

17
18 ^a Steno Diabetes Center Copenhagen, Gentofte, Denmark; narges.safai@regionh.dk

19
20 ^b Steno Diabetes Center Copenhagen, Gentofte, Denmark; bendix.carstensen@regionh.dk

21
22 ^c Novo Nordisk Foundation of Basic Metabolic Research, University of Copenhagen,
23
24 Denmark; Henrik.vestergaard@sund.ku.dk

25
26 ^d Novo Nordisk A/S, Søborg, Denmark and Department of Clinical Sciences, Lund
27
28 University, Malmö, Sweden; mtrd@novonordisk.com
29
30

31
32
33 Corresponding author:

34
35 Narges Safai, MD

36
37 Steno Diabetes Center Copenhagen

38
39 Niels Steensens Vej 2-4

40
41 DK-2820 Gentofte

42
43 Denmark

44
45 +45 3091 3395 (direct)

46
47
48 narges.safai@regionh.dk

49
50 Number of tables: 2

51
52 Number of figures: 3

53
54
55
56
57
58
59
60

1
2
3 **1 Abstract**

4 **2 Objectives:** To investigate the impact of a multifactorial treatment program in a real-life

5
6 3 setting on clinical outcomes and estimated cardiovascular disease (CVD) risk.

7
8 4 **Design:** A retrospective observational cohort study, using data from the electronic medical

9
10 5 records and national registers.

11
12 6 **Setting:** Tertiary diabetes centre in Denmark.

13
14 7 **Participants:** Patients with type 2 diabetes ($n=4,299$) referred to a program with focus on

15
16 8 treatment of hyperglycaemia, hypertension and dyslipidaemia, between Jan 1st 2001 and

17
18 9 April 1st 2016.

19
20
21 10 **Outcomes:** Primary outcomes were changes in HbA_{1c}, blood pressure and LDL cholesterol

22
23 11 as well as proportion reaching treatment targets. Our secondary outcome was to investigate

24
25 12 changes in antidiabetic, antihypertensive and lipid lowering treatment, together with the

26
27 13 impact on estimated CVD risk. Linear mixed model for repeated measurements were used for

28
29 14 continuous variables and logistic regression for dichotomous variables.

30
31 15 **Results:** The patients achieved a mean \pm SD decrease in HbA_{1c}, systolic and diastolic blood

32
33 16 pressure (BP), and LDL cholesterol of $1.0\pm 0.04\%$ (10.6 ± 0.4 mmol/mol), 6.3 ± 0.4 mmHg,

34
35 17 2.7 ± 0.2 mmHg and 0.32 ± 0.02 mmol/l, respectively ($p<0.0001$). The proportion of patients

36
37 18 who met the treatment goal for HbA_{1c} ($<7\%$ [<53 mmol/mol]) increased from 31% to 58% (p

38
39 19 <0.0001); for BP ($<130/80$ mm Hg) from 24% to 34% ($p <0.0001$), and for LDL cholesterol

40
41 20 (<2.5 mmol/l (patients without previous CVD) or <1.8 mmol/l (patients with previous CVD))

42
43 21 from 52% to 65%. Those reaching all three guideline treatment targets increased from 4% to

44
45 22 15% ($p<0.0001$), and when relaxing the BP target to $<140/85$ from 8% to 24%. The estimated

46
47 23 CVD risk was relatively reduced by 15.2% using the Swedish National Diabetes Register

48
49 24 Risk Engine and 30.9% using the UKPDS risk engine.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: Our data supports that short term multifactorial treatment of patients with glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and associated with a clinically meaningful improvement in CVD risk.

Strengths and limitations of this study

- Large cohort of dysregulated patients with type 2 diabetes under real-world conditions and strong validity of data with repeated recordings of clinical measurements and access to national registries.
- Selection bias in terms of more motivated and high risk patients being referred to the clinic, and by exclusion of those who did not show up.
- The use of risk engines can only give an estimate of the CVD risk and the UKPDS risk engine is based on a population many years prior to ours where treatment guidelines were different.

Keywords: Type 2 diabetes, glycaemic control, outcomes, CVD risk and multifactorial treatment

1 **Introduction**

2 Type 2 diabetes is an increasing global health threat. It is estimated that 439 million people
3 will be diagnosed with diabetes by 2030 (1). Type 2 diabetes is associated with an increased
4 risk of microvascular complications such as nephropathy, neuropathy, and retinopathy as well
5 as macrovascular disease, resulting in a decreased life expectancy and substantial personal
6 and societal expenses (2). Ensuring good glycaemic control remains the most effective
7 therapeutic measure to reduce the risk of developing microvascular disease (3, 4).

8 Multifactorial treatment with tight control of glycaemia, blood pressure (BP) and lipids,
9 accompanied by acetylsalicylic acid and lifestyle advice, is known to reduce progression of
10 microvascular complications, cardiovascular disease (CVD), and mortality by 50% in patients
11 with type 2 diabetes and microalbuminuria (5-7). Consequently, diabetes guidelines have
12 advocated an intensified treatment approach aiming at addressing and reducing all CVD risk
13 factors in patients with diabetes since several years (8, 9).

14
15 For most patients, sufficient glycaemic, BP and lipid control can be achieved in a primary
16 care setting but in high risk patients, or in patients with complex treatment regimens, the
17 proportion of patients who achieve metabolic control in primary care is lower (10, 11). In this
18 situation, in most health care systems, high risk patients are referred to specialist clinics for
19 evaluation. A broad risk factor intervention in this subgroup has proven particularly effective
20 in the Steno-2 study (5). However, it remains unknown whether the results seen in the study
21 setting can be achieved in clinical practice.

22
23 The overall aim of this study was to describe how the multifactorial intervention methods
24 from the Steno-2 study perform in a larger scale clinical setting. Our primary objective was to
25 describe changes in metabolic outcomes as a result of such structured short term intervention

1 and to test for gender differences. Our secondary objective was to describe the
2 pharmacological changes and to evaluate the impact on estimated CVD risk by using two
3 different risk assessment tools: the UKPDS Risk Engine (12), and the 5-year Swedish
4 National Diabetes Registry (NDR) risk model (13).

5 6 **Methods**

7 **Design and setting**

8 This study is based on patients referred to Steno Diabetes Center (SDC), a tertiary
9 multidisciplinary and highly specialized diabetes centre in the Capital Region of Denmark. It
10 serves as one out of three referral centres with a catchment area of over 1.7 million people
11 and provides diabetes care on a permanent basis to about 5.600 patients. During the Steno-2
12 study, SDC designed a treatment program algorithm specifically for patients with type 2
13 diabetes and glycaemic dysregulation. The primary goal of the program is to improve patient
14 quality of life and reduce mortality by prevention of acute and chronic complications of
15 diabetes. This is done by motivating and encouraging self-management, professional support
16 in behavioural changes, and pharmacological treatment according to national and
17 international guidelines. The SDC Type 2 Clinic (T2C) opened in 2001, providing care for
18 patients referred from general practitioners (GPs) or other hospitals in the region. Patients
19 were referred to the clinic either as newly diagnosed with a need for education and start of
20 treatment, requiring a shift to insulin treatment, having micro- or macrovascular
21 complications, or having glycaemic dysregulation in spite of attempts to control the disease
22 by the GP. The program, which is still running and is the same for all patients, involves a
23 consultation with a nurse, a dietician, and a physician in a structured order with specific
24 assignments and is comparable to the intensive treatment arm of the Steno-2 study (Figure 1).
25 The individual visits are, depending on the need, complemented by optional group-based

1 theme sessions with the overall aim of facilitating patient empowerment and with phone
2 consultations from a nurse. The treatment program consist of self-management training with
3 a focus on knowledge, lifestyle behaviour including diet, physical activity and smoking
4 cessation, skills to improve glycaemic control such as self-monitoring of blood glucose and
5 skills to prevent and identify complications. Furthermore, there is focus on pharmacological
6 treatment of hyperglycaemia, hypertension and dyslipidaemia. After approximately eight
7 months, patients were evaluated for referral back to their GP, or to continue at the SDC
8 outpatient clinic. The structure of program has remained unchanged in the study period while
9 e.g. medications used have followed updated treatment guidelines. The Danish treatment
10 guidelines have followed the international guidelines from EASD and ADA and were revised
11 in 2003, 2011 and 2014 (14-16). We defined the baseline and evaluation follow-up visits as
12 the first and last visit to the T2C, respectively. This study is a retrospective observational
13 study with demographics, clinical, and laboratory information extracted from the electronic
14 medical records and laboratory database of SDC.

15 16 Study population

17 We included all patients who had finalized a treatment program between 1st of January 2001
18 and 1st of April 2016 ($n = 4,489$), and to avoid no-shows, once off or very brief consultations
19 we excluded patients with a treatment duration under 30 days (i.e. between the baseline and
20 follow-up visits, $n = 190$). We ended up with a total of $n = 4,299$ patients. 16% of the patients
21 were subsequently re-referred to the clinic, but we only included their first treatment program
22 here. All data was anonymized prior to analysis.

23 24 Subject characteristics

1
2
3 1 Laboratory analyses at the baseline visit were encouraged to be fasting and included: glucose,
4
5 2 HbA_{1c}, haemoglobin, creatinine, total-cholesterol, high-density lipoprotein-cholesterol (HDL)
6
7 3 cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides (TG), C-peptide and
8
9 4 urine albumin. At all in-between visits and at follow-up an HbA_{1c}, BP and weight were
10
11 5 measured. All laboratory and anthropometric measurements were recorded using
12
13 6 standardized procedures at the SDC accredited laboratory (ISO 15189). Body mass index
14
15 7 (BMI) was calculated from weight and height (kg/m²). A person was considered overweight
16
17 8 at BMI ≥ 25 kg/m², and obese at BMI ≥ 30 kg/m². For BP and heart rate automated
18
19 9 oscillometric blood pressure recorders were used (AND UA-787plus, A&D medical,
20
21 10 California, USA). Smoking status was obtained at every visit.
22
23
24
25

26 12 Diabetes complications and pharmacological treatment

27
28 13 Micro albuminuria was here defined as a morning urine sample with urine albumin of 30-300
29
30 14 mg/L or urine albumin to creatinine ratio > 30 mg/g to 300 mg/g at the first visit. Macro
31
32 15 albuminuria likewise but with a value > 300 mg/L or > 300 mg/g. Peripheral neuropathy was
33
34 16 defined by examining vibration sensation with a biothesiometer and using an age-adjusted
35
36 17 threshold (17). Information on cardiovascular disease was obtained from The National Patient
37
38 18 Register and included diagnosis from 1977 till 2015 and procedures from 1995 till 2015.
39
40 19 Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery,
41
42 20 ischaemic heart disease, heart insufficiency, atrial fibrillation, vascular surgery, stroke,
43
44 21 transitory cerebral ischaemia and amputations using ICD-8 and ICD-10 codes.
45
46 22 Information on medication was obtained by Register of Medicinal Products Statistics, where
47
48 23 individual-level data on all prescription drugs sold in Danish community pharmacies since
49
50 24 1994 has been recorded and administered by Statistics Denmark (18). A person was defined
51
52 25 as being on a treatment at baseline if they had purchased a prescribed drug less than 180 days
53
54
55
56
57
58
59
60

1 before their first visit and at follow-up if they purchased a prescribed drug after their first
2 visit and less than 30 days after their last visit.

3 Permission to use data has been obtained from the Danish Data Protection Agency (ref.
4 number: 2007-58-0015) and from the Danish Patient Safety Authority. According to Danish
5 Committee law register studies do not require an approval from the National Committee on
6 Health Research Ethics.

7 8 CVD risk

9 To evaluate the effect of changes in metabolic outcomes on the estimated risk of CVD, we
10 calculated CVD risk at baseline and at follow-up using two different risk assessment tools: a
11 Swedish risk model specific for type 2 diabetes (13) and the UKPDS Risk Engine (12). The
12 Swedish model is based on patients with type 2 diabetes using 12 predictors: sex, age,
13 diabetes duration, TG, HDL cholesterol, HbA_{1c}, systolic BP, BMI, smoking status,
14 albuminuria, atrial fibrillation and previous CVD. It is derived from a large observational
15 sample of patients ($n = 24,288$) in the Swedish National Diabetes Register (NDR) followed
16 from 2002 to 2007 and estimates the 5-year risk of CVD. The UKPDS Risk Engine is also
17 type 2 diabetes-specific and based on 4,540 patients from the UKPDS trial (1977 to 1991). It
18 includes HbA_{1c} as a continuous variable and calculates the risk of developing a new coronary
19 heart disease (CHD) event.

20 21 Statistical methods

22 The primary outcomes were changes in blood glucose control (HbA_{1c}), BP and lipids from
23 first visit (baseline) to end of treatment (follow-up evaluation visit) and to explore gender
24 differences in outcomes. Furthermore we investigated how many patients reached the
25 recommended targets for HbA_{1c} (A), BP (B) and LDL cholesterol (C) according to national

1 guidelines (14), collectively referred to as ABC control: HbA_{1c} < 7% (< 53 mmol/mol), BP <
2 130/80 mm Hg and LDL cholesterol < 2.5 mmol/l (< 100 mg/dl, patients without previous
3 CVD) or < 1.8 mmol/l (< 70 mg/dl, patients with previous CVD). For blood lipids, the T2C
4 program assumed they would not deteriorate if they were on target at baseline and
5 measurements were only repeated in case they were not at target at baseline. Accordingly, for
6 this analysis a last observation carried forward approach was used to impute missing data. *T*
7 test was used to test for gender differences at baseline or at follow-up. Comparison between
8 baseline and follow-up was made using mixed model for repeated measurements (MMRM)
9 for continuous variables adjusting for gender and baseline values and with the subject as a
10 random effect. For dichotomous variables e.g. pharmacological treatment, logistic regression
11 models were used adjusting for gender. McNemar test was used to compare changes in
12 categorical variables. For risk estimates, exact 95%-confidence intervals (CI) were
13 calculated. SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC) was used for database
14 management and all of the above-mentioned analyses.

16 Results

18 Study cohort characteristics

19 Baseline characteristics of the study cohort are shown in Table 1. The majority of patients
20 were Caucasians, and 19% were diagnosed with diabetes within a year before their referral.
21 There were more males ($n = 2,567$) than females ($n = 1,732$) but no difference in treatment
22 duration: median treatment program duration was 8.4 months (IQR: 6.1, 11.3). There were
23 more male smokers and ex-smokers. Males had a higher level of HbA_{1c}, BP, weight and TG
24 but lower BMI and cholesterol levels at baseline (Table 1).

1 Metabolic outcomes

2 There was a significant decrease in HbA_{1c} between baseline and follow-up of $1.0 \pm 0.04\%$
3 (10.6 ± 0.4 mmol/mol), with no gender difference. The decrease in systolic BP was 6.3 ± 0.4
4 mm Hg and in diastolic BP 2.7 ± 0.2 mm Hg ($p < 0.0001$ for both). The effect of treatment on
5 BP was the same in both genders. There was a significant decrease in total-cholesterol, LDL
6 and TG of 0.39 ± 0.03 mmol/l, 0.32 ± 0.02 mmol/l and 0.22 ± 0.05 mmol/l, respectively.
7 There was no change in HDL levels overall ($p = 0.2$). As expected, females had higher HDL
8 levels than males, both at baseline and at follow-up ($p < 0.0001$). This gender difference was
9 also seen for total- and LDL cholesterol levels where females had higher levels at both
10 baseline and follow-up. The effect of treatment on lipid levels was equal in both genders.

12 ABC control

13 In general, the proportion of patients achieving full ABC control according to national
14 guideline treatment targets increased from 4% to 15% ($p < 0.0001$). More females were
15 achieving all three treatment targets at both baseline ($p = 0.047$) and at follow-up ($p = 0.014$).
16 Patients achieving the HbA_{1c} target increased from 31% to 58% ($p < 0.0001$), the BP target
17 from 24% to 34% ($p < 0.0001$), and the LDL target from 52% to 65% ($p = 0.002$, Figure 2).
18 If the BP target was relaxed from $< 130/80$ mm Hg to $< 140/85$ mm Hg the percentage
19 achieving the BP target increased from 43% at baseline to 58% at follow-up ($p < 0.0001$),
20 and consequently full ABC control from 8% at baseline to 24% at follow-up ($p < 0.0001$).

22 Changes in pharmacological treatment

23 The most common antidiabetic drug at baseline was metformin, which 58.4% of the patients
24 were on, followed by sulphonyl urea (SU), 38.4%, and insulin, 19.5% (Figure 3). Only a
25 small proportion of patients were on dipeptidyl peptidase 4 (DPP-4) inhibitors, 7.0%,

1 glucagon-like peptide 1 (GLP-1) analogues, 3.9%, or other antidiabetic drug, 4.2%. In
2 general there was an increase in the use of medication during the program. The largest
3 increase was seen in use of metformin to 75.3%, insulin to 36.9% and GLP1-analogues to
4 11.6%. While SU only increased slightly to 41.8%, DPP-4 inhibitors to 9.6% and other
5 antidiabetics 4.3%.

6 As part of the multifactorial treatment program, we also observed an increase in use of
7 antihypertensive drugs to 75.3%, lipid lowering drugs to 75.9% and acetylsalicylic acid
8 (ASA) to 69.6%.

9 10 Changes in cardiovascular risk

11 Estimated baseline and follow-up cardiovascular risk according to the used risk engines are
12 shown in Table 2. Using the Swedish NDR model which predicts the 5 year risk of a new
13 CVD event in a diabetic population, we observed a relative risk reduction of 15.2% (95% CI:
14 14.5-15.9). The UKPDS risk engine showed a relative risk reduction of 30.9% (95% CI:
15 30.3-31.5) in the 5 year CHD risk estimate. Females had a lower risk than males both at
16 baseline and at follow-up according to both risk models ($p < 0.0001$). Meanwhile, both
17 according to the Swedish NDR model and the UKPDS risk engine, females had a smaller
18 relative risk reduction compared to males ($p < 0.0001$).

19 20 **Discussion**

21
22 This study shows that a short term targeted multifactorial treatment program in a specialized
23 clinical setting can improve metabolic outcome measures and CVD risk in patients with type
24 2 diabetes and high prevalence of complications. This confirms that multifactorial treatment
25 not only works in a clinical study setting, but is also feasible and effective in real world

1 clinical practice. With a specialized group of health care providers and a structured treatment
2 and educational program that focuses on lifestyle intervention, self-management training and
3 pharmacological treatment of hyperglycaemia, hypertension and dyslipidaemia, it is possible
4 to accomplish significant CVD risk reductions in a high risk population with diabetes.

5 6 ABC control

7 Intensive multifactorial intervention in high risk patients has previously been shown to reduce
8 CVD and mortality (7), and a recent 21 years follow-up of the Steno-2 study population
9 shows that patients in the intensive-therapy group survived for a median of 7.9 years longer
10 than the conventional-therapy group patients (19). Here we show that the same treatment
11 program also works in clinical practice in a more diverse population, and results in a
12 substantial reduction of 5- and 10-year CVD risk as estimated by two of the available and
13 commonly used risk engines. In terms of risk factor intervention, glucose control continuous
14 to be the greatest challenge to diabetes care. Nonetheless, all but 21% of patients changed
15 from a higher to a lower HbA_{1c} category in this follow-up. Importantly, the improvement in
16 glycaemic control was not accompanied by a general increase in weight. In fact, although we
17 found that 15% of those in the normal weight category shifted to the overweight category
18 when comparing the changes in BMI categories, 15% of those who were in the obese or
19 overweight category dropped to a lower weight category. The weight gain observed in some
20 patients is probably explained by the increased use of insulin, while weight loss in others can
21 be explained by an increased use of GLP-1 receptor agonist treatment in recent years along
22 with lifestyle management including dietary and physical activity advice.

23
24 With focus on hyperglycaemia, hypertension and dyslipidaemia, we found an increase in the
25 proportion of patients achieving the recommended targets that are comparable to intervention

1 studies (20, 21). Here, the relative proportion of patients achieving $HbA_{1c} < 53$ mmol/mol
2 (7%) nearly doubled, BP < 130/80 mm Hg increased by 42% and LDL < 2.5 mmol/l by 25%.
3 The T2C treatment program in this complex high-risk cohort resulted in a higher prevalence
4 of risk factors in control equal to what has been observed in the more general diabetes
5 population in the National Health and Nutrition Examination Surveys (NHANES) from 2007
6 to 2010 (22). The NHANES data differ in the way that their data was cross-sectional with
7 participants with self-reported diabetes, without any distinction between type 1 and type 2,
8 and with a different risk profile. Our population was more selected by being referred from
9 their GP and requiring specialized care, which means they either had more comorbidities or a
10 more complex treatment than the general patient with type 2 diabetes. For HbA_{1c} 58% in our
11 cohort achieved the treatment target vs 53% in the NHANES cohort and for LDL-cholesterol
12 65% vs 56%, respectively. But for BP there was a big difference, 34% in our cohort vs. 51%
13 in the NHANES cohort. This could be due to a higher prevalence of high BP in this group of
14 patients selected with complex disease and long diabetes duration. We did observe a time
15 trend in the data as the proportion of patients achieving the stringent BP target increased from
16 23% in 2001 to 44% in 2015. The same improvement trend over time was observed in the
17 proportion of patients achieving all three ABC targets; 7% in 2001 increasing to an average
18 of 16% from 2006 and forward in our material and in the NHANES data from 7% in 1999-
19 2002 to 19% in 2007-2010.

20 CVD risk

21 To estimate the CVD risk in patients with type 2 diabetes is helpful to follow-up on treatment
22 and to target further measures to patients at risk. In this study we used two different CVD risk
23 engines to estimate the effect of the treatment program. The UKPDS risk engine is diabetes-
24 specific and has several advantages as it incorporates HbA_{1c} and diabetes duration as
25

1 continuous variables (12). However, it is still not ideal as it is based on the patients recruited
2 by UKPDS for randomization in a clinical trial two decades ago before newer and more
3 effective treatments were available or widely used (e.g. statins, angiotensin converting
4 enzyme inhibitors and antidiabetic drugs). Accordingly, recent validation showed poor
5 calibration and overestimation of the CHD risk (23). A model that seems more suitable for
6 our population is the Swedish NDR risk model, which is based on a more recent and
7 nationwide population, reflecting a more diverse population and taking into account the
8 history of previous CVD and BMI. By using this model we found a relative reduction in the
9 estimated 5-year CVD risk of 16%, after approximately eight months, despite the increase in
10 age and diabetes duration. Notably, the fact that 26% of the patients had a prior CVD
11 diagnosis at baseline reflects the high risk profile and complexity of the population that was
12 referred to the treatment program. This of course does not normalise their actual risk, which
13 will still be high, but can be a motivating factor for the patients that there are some
14 modifiable risk factors that can reduce their risk. In comparison, the population used in the
15 Swedish model had a mean risk of 11.9% and a 5-year risk of fatal/non-fatal CVD of more
16 than 10% is defined as high risk. According to this 92% of our population was in high risk at
17 baseline. The UKPDS risk engine which estimates the risk of the first CHD event in 5 or 10
18 years, gives a lower 5 and 10 year risk estimate at baseline than the Swedish model, 7.4% and
19 17.1% respectively. This is nearly the same as the 10-year risk found in a NHANES
20 population from 2007 to 2012 of 16.5% if no risk factors were in control and 10.2% if all risk
21 factors were in control when using the same risk engine (24).

22 Interestingly, both the NDR and UKPDS risk engines estimated a higher risk reduction in
23 males than in females. This, perhaps expected finding, could be due to the higher CVD risk in
24 males at baseline, but could also be due to a relatively greater HbA_{1c} reduction seen in males,
25 which is used in both the NDR and the UKPDS risk engines. However, the gender difference

1 remained significant after excluding HbA_{1c} from the equation. This in spite a higher
2 percentage of females achieved the metabolic targets.

3 4 Strengths and limitations

5 Strengths of this study include the validity of data with repeated recordings of the HbA_{1c} and
6 BP at each visit, and that it includes a large cohort of patients treated under real-life
7 conditions such that results might have greater external validity than the highly selected
8 populations in randomized controlled trials (RCT). Still, we cannot rule out that there might
9 be a selection bias in terms of more motivated patients being referred to the clinic, and by
10 exclusion of those who did not show up.

11 As a result of using a database and a register, we do not have complete data on all patients
12 and therefore the cohort size changes a bit as results are based on those without missing
13 values. Another limitation is that there is a lack of patient reported outcomes, such as adverse
14 events of drugs and general well-being. This was not possible to extract from the electronic
15 medical records. Furthermore we cannot be sure that the patients going through a treatment
16 program actually completed the program or was discharged for other reasons. It is also
17 important to acknowledge that most of the treatment programs analysed here were completed
18 before many of the new anti-diabetic treatments, as GLP1-analogs and sodium-glucose co-
19 transporter 2 (SGLT2)-inhibitors, were widely used and before acceptance of a more
20 personalized treatment as recommended in the position statement from ADA and EASD in
21 2012 (16). Another limitation of this study is the use of risk engines that only give an
22 estimate of the CVD or CHD risk and that UKPDS is based on a population many years prior
23 to ours and treatment guidelines were not the same.

24 Meanwhile, the data serves as a baseline benchmark for real world data studies as to what can
25 be achieved in routine clinical practice before these treatments and guidelines get wider use

1 and implementation. The use of a more individualized treatment approach with involvement
2 of the patient in decision making is increasingly used in the treatment programs at the
3 moment and is expected to increase adherence to therapy. Furthermore, the combination of a
4 more individualized HbA_{1c} target and a broader selection of antidiabetic, antihypertensive
5 and dyslipidaemia treatment will likely increase the proportion of patients achieving their
6 treatment goals and thereby reduce their CVD risk and mortality. Specifically, since the
7 EMPA-REG OUTCOME trial showed a 38% and the LEADER trial a 22% relative risk
8 reduction in deaths from CVD events in patients with type 2 diabetes and a high risk of
9 cardiovascular events (25, 26), this gives us further treatment options in this patient group.
10 Therefore constant evaluation of the effects of our treatments on the risk of CVD or mortality
11 is necessary. Combining these drugs, the treatment program evaluated here, and an
12 individualized approach would be a logical next step for future studies.

13 14 Conclusion

15 This study of patients with type 2 diabetes who undergo structured treatment program lasting
16 less than one year show that it is possible to increase the proportion of patients achieving the
17 target levels for HbA_{1c}, BP, and LDL, thereby reducing their estimated CVD and CHD risk.
18 To the strengths of such a structured program we count the focus on treatment targets by a
19 multidisciplinary team and the fact that it is time limited, which reduces clinical inertia and
20 costs. Our results show that intensive treatment is not only effective in the RCT setting, but
21 also in clinical practice and should encourage other health care systems to establish similar
22 programs.

23

24

1

2 Conflicts of interest

3 NS, BC and HV were employed at Steno Diabetes Center A/S, now known as Steno Diabetes
4 Center Copenhagen and MR was employed there when the study was initiated. Steno
5 Diabetes Center A/S was a research hospital working in the Danish National Health Service
6 and owned by Novo Nordisk A/S. NS and BC own shares in Novo Nordisk A/S.

7 Funding

8 This study has been funded by Innovation Fund Denmark

9 Contribution statement

10 NS and BC were responsible for data management and statistical analysis. NS and MR were
11 responsible for interpretation of data and writing of the article. HV was responsible
12 interpretation and critical revision of the article. All authors fully approved the final version
13 of the article.

14 Data sharing statement

15 Clinical data will be available at request, but information on diagnosis and medication is not
16 allowed to be shared by the Danish National Patient Register or Statistics Denmark.

17

18 Uncategorized References

- 19 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE.
20 Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes*
21 *research and clinical practice*. 2014;103(2):137-49.
- 22 2. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et
23 al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a
24 collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-
25 22.
- 26 3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of
27 intensive glucose control in type 2 diabetes. *The New England journal of medicine*.
28 2008;359(15):1577-89.
- 29 4. UKPDS. Effect of intensive blood-glucose control with metformin on
30 complications in overweight patients with type 2 diabetes (UKPDS 34). *UK Prospective*
31 *Diabetes Study (UKPDS) Group. Lancet*. 1998;352(9131):854-65.
- 32 5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.
33 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
34 *The New England journal of medicine*. 2003;348(5):383-93.

- 1 6. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin
2 compared with conventional treatment and risk of complications in patients with type 2
3 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*.
4 1998;352(9131):837-53.
- 5 7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a
6 multifactorial intervention on mortality in type 2 diabetes. *The New England journal of*
7 *medicine*. 2008;358(6):580-91.
- 8 8. IDF Clinical Guidelines Task Force. Global guideline for Type 2
9 diabetes. . Brussels: International Diabetes Federation; 2005.
- 10 9. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F,
11 et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed
12 in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and
13 cardiovascular diseases of the European Society of Cardiology (ESC) and developed in
14 collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart*
15 *J*. 2013;34(39):3035-87.
- 16 10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, et al.
17 EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk
18 patients in general practice: cross-sectional survey in 12 European countries. *Eur J*
19 *Cardiovasc Prev Rehabil*. 2010;17(5):530-40.
- 20 11. Alonso-Fernandez M, Mancera-Romero J, Mediavilla-Bravo JJ, Comas-
21 Samper JM, Lopez-Simarro F, Perez-Unanua MP, et al. Glycemic control and use of A1c
22 in primary care patients with type 2 diabetes mellitus. *Prim Care Diabetes*.
23 2015;9(5):385-91.
- 24 12. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective
25 Diabetes Study G. The UKPDS risk engine: a model for the risk of coronary heart disease
26 in Type II diabetes (UKPDS 56). *Clin Sci (Lond)*. 2001;101(6):671-9.
- 27 13. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S,
28 Cederholm J, et al. A new model for 5-year risk of cardiovascular disease in type 2
29 diabetes, from the Swedish National Diabetes Register (NDR). *Diabetes research and*
30 *clinical practice*. 2011;93(2):276-84.
- 31 14. Sundhedsstyrelsen CfEoMT. Type 2-diabetes. Medicinsk teknologivurdering
32 af screening, diagnostik og behandling 2003 [Available from:
33 <https://www.sst.dk/~media/F42943CEAEC743DDAD8CB57FF55C9581.ashx>.
34
- 35 15. Snorgaard O DT, Breum L et al. Farmakologisk behandling af type 2-
36 diabetes – mål og algoritmer - 2014 2014 [Available from:
37 <http://www.endocrinology.dk/PDF/FarmakologiskbehandlingDM2rev2014.pdf>.
38
- 39 16. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et
40 al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach.
41 Position statement of the American Diabetes Association (ADA) and the European
42 Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55(6):1577-96.
- 43 17. Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure
44 individual vibration thresholds and their variation in 519 non-diabetic subjects. *Br Med J*
45 *(Clin Res Ed)*. 1984;288(6433):1793-5.
- 46 18. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription
47 Registry. *Scand J Public Health*. 2011;39(7 Suppl):38-41.
- 48 19. Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving
49 HH, et al. Years of life gained by multifactorial intervention in patients with type 2
50 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised
51 trial. *Diabetologia*. 2016.
- 52 20. Tight blood pressure control and risk of macrovascular and microvascular
53 complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ*.
54 1998;317(7160):703-13.
- 55 21. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A,
56 et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes
in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-
randomised trial. *Lancet*. 2011;378(9786):156-67.

- 1
2
3 1 22. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The
4 2 prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes,
5 3 1988-2010. *Diabetes Care*. 2013;36(8):2271-9.
6 4 23. Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, et
7 5 al. External validation of the UKPDS risk engine in incident type 2 diabetes: a need for
8 6 new type 2 diabetes-specific risk equations. *Diabetes Care*. 2014;37(2):537-45.
9 7 24. Wong ND, Patao C, Malik S, Iloeje U. Preventable coronary heart disease
10 8 events from control of cardiovascular risk factors in US adults with diabetes (projections
11 9 from utilizing the UKPDS risk engine). *Am J Cardiol*. 2014;113(8):1356-61.
12 10 25. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
13 11 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New*
14 12 *England journal of medicine*. 2015;373(22):2117-28.
15 13 26. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck
16 14 MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *The New England*
17 15 *journal of medicine*. 2016;375(4):311-22.
18
19
20
21
22
23
24
25
26

20 **Figure legends**

21 Figure 1 - Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and
22 consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1
23 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'.
24 Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation
25 and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit
26 with nurse, dietician and endocrinologist. After approximately 8 months patients with no
27 complications are referred back to general practice and those with micro- or macrovascular
28 complications are referred to the outpatient clinic.

29
30 Figure 2 - Proportion of patients achieving the treatment targets for HbA_{1c}, LDL cholesterol,
31 systolic and diastolic blood pressure at baseline and at follow-up.

32
33 Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up.

Table 1 Baseline characteristics of the study cohort

	N	All	Females (<i>n</i> = 1,732)	Males (<i>n</i> = 2,567)
Age (years)	4,299	59.3 (12.4)	59.9 (12.9)	58.9 (12.1)
Weight (kg)	4,256	91.5 (21.2)	84.4 (20.4)	96.3 (20.4)
Body mass index (kg/m ²)	4,236	31.0 (6.6)	31.8 (7.4)	30.3 (4.4)
Smokers, N (%)	4,071	1,629 (37.9)	622 (35.9)	1,007 (39.5)
Caucasians, N (%)	4,289	3,724 (87)	1,457 (84)	2,267 (89)
Diabetes and complications				
Duration of type 2 diabetes (years)	4,252	7.1 (6.5)	7.3 (6.6)	6.9 (6.5)
Diabetes duration < 1 year, N (%)	4,252	828 (19.5)	311 (18.1)	517 (20.4)
GAD65 antibodies ≥25 U/mL, N (%)	2,376	116 (2.7)	59 (3.4)	57 (2.2)
HbA _{1c} (%)	4,253	8.2 (3.9)	8.1 (3.9)	8.2 (19)
HbA _{1c} (mmol/mol)	4,253	66 (19)	65 (19)	66 (19)
Fasting p-glucose (mmol/L)	2,850	9.9 (3.6)	9.6 (3.4)	10.0 (3.7)
Fasting c-peptide (pmol/L) Median (IQR)	2,898	1050 (706-1500)	1050 (699–1517)	1050 (711-1478)
Prior cardiovascular disease, N (%)†	4,299	1,127 (26)	400 (23)	727 (28)
Microalbuminuria, N (%)	4,299	787 (18)	254 (15)	533 (21)
Macroalbuminuria, N (%)	4,299	211 (5)	47 (3)	164 (6)
eGFR (mL/min)	1,335	78 (17)	77 (18)	79 (16)
Simple retinopathy, N (%)	3,859	1134 (29)	422 (27)	712 (31)
Proliferative retinopathy, N (%)	3,859	56 (1)	25 (2)	31 (1)
Peripheral neuropathy, N (%)	2,343	549 (23)	140 (15)	409 (29)
Blood pressure				
Systolic blood pressure (mm Hg)	4,280	141.7 (21.7)	140.5 (22.5)	142.6 (21.1)

Table 1 Baseline characteristics of the study cohort

	N	All	Females (<i>n</i> = 1,732)	Males (<i>n</i> = 2,567)
Diastolic blood pressure (mm Hg)	4,280	82.5 (11.5)	80.8 (11.4)	83.6 (11.5)
Lipids				
Total cholesterol (mmol/L)	3,946	4.7 (1.2)	4.9 (1.3)	4.6 (1.2)
LDL cholesterol (mmol/L)	3,946	2.5 (1.0)	2.6 (1.0)	2.5 (1.0)
HDL cholesterol (mmol/L)	3,946	1.2 (0.4)	1.3 (0.4)	1.2 (0.4)
Triglycerides (mmol/L) Median (IQR)	3,946	1.7 (1.2–2.5)	1.7 (1.2–2.5)	1.7 (1.2–2.6)
Medication				
Metformin, N (%)	4,299	2511 (58)	1025 (59)	1486 (58)
Sulfonylurea, N (%)	4,299	1652 (38)	673 (39)	979 (38)
DPP-4 inhibitor, N (%)	4,299	303 (7)	126 (7)	177 (7)
GLP-1 analogue, N (%)	4,299	168 (4)	73 (4)	95 (4)
Insulin, N (%)	4,299	836 (19)	346 (20)	490 (19)
Other OAD, N (%)	4,299	179 (4)	67 (4)	112 (4)
RAS blockade, N (%)	4,299	2027 (47)	736 (17)	1291(30)
All antihypertensive drugs, N (%)	4,299	2678 (62)	1099 (26)	1579 (37)
Lipid lowering drug, N (%)	4,299	1988 (46)	776 (45)	1212 (47)
Acetylsalicylic acid, N (%)	4,299	1538 (36)	530 (31)	1008 (39)

Values are means (SDs) unless stated otherwise.

†Prior CVD was defined as one or more of the following: myocardial infarction, heart surgery, ischaemic heart disease, heart insufficiency, vascular surgery, stroke, transitory cerebral ischaemia, amputation.

CVD, cardiovascular disease; GAD, glutamic acid decarboxylase; HbA_{1c}, haemoglobin A_{1c}; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DPP-4, Dipeptidyl peptidase 4; GLP-1, Glucagon-like peptide 1; OAD, oral antidiabetic drug; RAS, Renin angiotensin system.

Table 2 Estimated CVD or CHD risk

	Baseline	Follow-up
Estimated CVD 5-year risk: NDR Risk engine:		
All	29.8 (19.6-44.6) ^a	25.0 (16.6-37.4) ^{b,*}
F	24.9 (15.9-37.0)	21.1 (13.7-31.1)*
M	34.0 (22.6-48.2)	28.1 (19.1-41.2)*
Estimated CHD 5-year risk: UKPDS Risk Engine:		
All	7.4 (3.9-13.7) ^c	5.0 (2.7-9.2) ^{d,*}
F	4.8 (2.6-8.7)	3.3 (1.9-5.9)*
M	9.6 (5.3-16.7)	6.4 (3.7-11.3)*
Estimated CHD 10-year risk: UKPDS Risk Engine:		
All	17.1 (9.3-30.4) ^c	11.8 (6.5-21.1) ^{d,*}
F	11.4 (6.1-20.0)	7.9 (4.5-14.0)*
M	22.1 (12.6-36.2)	15.0 (9.0-25.4)*

Estimated CVD risk according to the Swedish National Register (NDR) risk engine and the estimated CHD risk according to the UKPDS risk engine. Data is median risk in % (IQR).

a $n = 3,865$; b $n = 3,730$; c $n = 3,895$; d $n = 3,757$, * $P < 0.0001$.




Figure 1 - Flow chart of the treatment program. Visit A: Visit at the laboratory, eye clinic and consultation with nurse. Visit B: Consultation with nurse, dietician and physician. Visit C1 and C2: Individual program with nurse. Group sessions: Module A: 'Me and my diabetes'. Module B: 'My feet and physical activity'. Module C: 'My diet'. Module D: 'My motivation and future lifestyle plans'. Visit C: Consultation with nurse and dietician. Visit D: Final visit with nurse, dietician and endocrinologist. After approximately 8 months patients with no complications are referred back to general practice and those with micro- or macrovascular complications are referred to the outpatient clinic.

121x170mm (300 x 300 DPI)




Figure 2 - Proportion of patients achieving the treatment targets for HbA1c, LDL cholesterol, systolic and diastolic blood pressure at baseline and at follow-up.

183x174mm (300 x 300 DPI)






Figure 3 - Proportion of patients on pharmacological treatment at baseline and follow-up.

156x120mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	21 (Table 1)
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.